

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
30 June 2005 (30.06.2005)

PCT

(10) International Publication Number
WO 2005/058913 A1

(51) International Patent Classification⁷: **C07D 498/18**,
471/18, 471/04, 487/04, A61K 31/519, A61P 35/00

(21) International Application Number:
PCT/EP2004/053501

(22) International Filing Date:
15 December 2004 (15.12.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/EP03/51062
18 December 2003 (18.12.2003) EP
PCT/EP03/51058
18 December 2003 (18.12.2003) EP

(71) Applicant (for all designated States except US):
JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **FREYNE, Eddy, Jean, Edgard** [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **WILLEMS, Marc** [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **STORCK, Pierre, Henri** [FR/FR]; Johnson & Johnson Pharmaceutical, Research and Development, Campus de Maigremont, BP 615, F-27106 Val de Reuil Cedex (FR). **PONCELET, Virginie, Sophie** [FR/FR]; Johnson & Johnson Pharmaceutical, Research and Development, Campus de Maigremont, BP 615, F-27106 Val de Reuil Cedex (FR). **VAN EMELEN, Kristof** [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **BUIJNSTERS, Peter, Jacobus, Johannes, Antonius** [NL/NL]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340

Beerse (BE). **EMBRECHTS, Werner, Constant, Johan** [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **PERERA, Timothy, Pietro, Suren** [GB/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).

(74) Common Representative: **JANSSEN PHARMACEUTICA N.V.**; Turnhoutseweg 30, B-2340 Beerse (BE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY,

[Continued on next page]

(54) Title: PYRIDO- AND PYRIMIDOPYRIMIDINE DERIVATIVES AS ANTI-PROLIFERATIVE AGENTS



(57) Abstract: The present invention concerns the compounds of formula (I) the *N*-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein a¹-a²=a³-a⁴ represents a divalent radical selected from N-CH=CH-CH, N-CH N-CH or CH-CH=N-CH; Z represents NH; Y represents -C₃₋₆alkyl-, -C₁₋₅alkyl-NR¹³-, -C₁₋₆alkyl-NH-CO- or -CO-NH-C₁₋₆alkyl-; X¹ represents -O- or -NR¹¹-; X² represents -C₁₋₂alkyl-, -O-C₁₋₂alkyl-, -O- or -O-CH₂-; R¹ represents hydrogen or halo; R² represents hydrogen, cyano, halo, hydroxycarbonyl-C₁₋₄alkyloxycarbonyl-, Het¹⁶-carbonyl- or Ar⁵; R³ represents hydrogen; R⁴ represents hydroxy, C₁₋₄alkyloxy-, Ar⁴-C₁₋₄alkyloxy or R⁴ represents C₁₋₄alkyloxy substituted with one or where possible two or more substituents selected from C₁₋₄alkyloxy- or Het²-; R¹¹ represents hydrogen; R¹² represents hydrogen, C₁₋₄alkyl- or C₁₋₄alkyl-oxy-carbonyl-;

R¹³ represents Het¹⁴-C₁₋₄alkyl, in particular morpholinyl-C₁₋₄alkyl; Het² represents a heterocycle selected from morpholinyl or piperidinyl optionally substituted with C₁₋₄alkyl-, preferably methyl; Het¹⁴ represents morpholinyl; Het¹⁶ represents a heterocycle selected from morpholinyl or pyrrolidinyl; Ar⁴ represents phenyl; Ar⁵ represents phenyl optionally substituted with cyano.



TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations

— of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

PYRIDO- AND PYRIMIDOPYRIMIDINE DERIVATIVES
AS ANTI-PROLIFERATIVE AGENTS

This invention relates to pyrimidopyrimidine derived macrocycles that have
5 been found to possess anti-proliferative activity, such as anti-cancer activity and are
accordingly useful in methods of treatment of the human or animal body, for example
in the manufacture of medicaments for use in hyper proliferative disorders such as
atherosclerosis, restenosis and cancer. The invention also relates to processes for the
manufacture of said pyrimidopyrimidine derivatives, to pharmaceutical compositions
10 containing them and to their use in the manufacture of medicaments of use in the
production of anti-proliferative effect .

In particular, the compounds of the present invention were found to inhibit
tyrosine kinase enzymes, also called tyrosine kinases. Tyrosine kinases are a class of
enzymes, which catalyse the transfer of the terminal phosphate of adenosine
15 triphosphate to the phenolic hydroxyl group of a tyrosine residue present in the target
protein. It is known, that several oncogenes, involved in the transformation of a cell
into a malignant tumour cell, encode tyrosine kinase enzymes including certain growth
factor receptors such as EGF, FGF, IGF-1R, IR, PDGF and VEGF. This family of
receptor tyrosine kinases and in particular the EGF family of receptor tyrosine kinases
20 are frequently present in common human cancers such as breast cancer, non-small cell
lung cancers including adenocarcinomas and squamous cell cancer of the lung, bladder
cancer, oesophageal cancer, gastrointestinal cancer such as colon, rectal or stomach
cancer, cancer of the prostate, leukaemia and ovarian, bronchial or pancreatic cancer,
which are examples of cell proliferation related disorders.

25 Accordingly, it has been recognised that the selective inhibition of tyrosine
kinases will be of value in the treatment of cell proliferation related disorders. Support
for this view is provided by the development of Herceptin® (Trastuzumab) and
Gleevec™ (imatinib mesylate) the first examples of target based cancer drugs.
30 Herceptin® (Trastuzumab) is targeted against Her2/*neu*, a receptor tyrosine kinase
found to be amplified up to 100-fold in about 30% of patients with invasive breast
cancer. In clinical trials Herceptin® (Trastuzumab) proved to have anti-tumour activity
against breast cancer (Review by L.K. Shawer *et al*, "Smart Drugs: Tyrosine kinase
inhibitors in cancer therapy", 2002, Cancer Cell Vol.1, 117), and accordingly provided
35 the proof of principle for therapy targeted to receptor tyrosine kinases. The second
example, Gleevec™ (imatinib mesylate), is targeted against the abelson tyrosine kinase

-2-

(Bcr-Abl), a constitutively active cytoplasmic tyrosine kinase present in virtually all patients with chronic myelogenous leukaemia (CML) and 15% to 30% of adult patients with acute lymphoblastic leukaemia. In clinical trials Gleevec™ (imatinib mesylate) showed a spectacular efficacy with minimal side effects that led to an approval within 3 months of submission. The speed of passage of this agent through clinical trials and regulatory review has become a case study in rapid drug development (Drucker B.J. & Lydon N., "Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukaemia.", 2000, J.Clin.Invest. 105, 3).

Further support is given by the demonstration that EGF receptor tyrosine kinase inhibitors, specifically attenuates the growth in athymic nude mice of transplanted carcinomas such as human mammary carcinoma or human squamous cell carcinoma (Review by T.R. Burke Jr., *Drugs of the Future*, 1992, 17, 119). As a consequence, there has been considerable interest in the development of drugs to treat different cancers that target the EGFR receptor. For example, several antibodies that bind to the extra-cellular domain of EGFR are undergoing clinical trials, including Erbitux™ (also called C225, Cetuximab), which was developed by Imclone Systems and is in Phase III clinical trials for the treatment of several cancers. Also, several promising orally active drugs that are potent and relatively specific inhibitors of the EGFR tyrosine kinase are now well advanced in clinical trials. The AstraZeneca compound ZD1839, which is now called IRESSA® and approved for the treatment of advanced non-small-cell lung cancer, and the OSI/Genentech/Roche compound OSI-774, which is now called Tarceva™ (erlotinib), have shown marked efficacy against several cancers in human clinical trials (Morin M.J., "From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumour and anti-angiogenic agents, 2000, *Oncogene* 19, 6574).

In addition to the above, EGF receptor tyrosine kinases has been shown to be implicated in non-malignant proliferative disorders such as psoriasis (elder *et al.*, *Science*, 1989, 243; 811). It is therefore expected that inhibitors of EGF type receptor tyrosine kinases will be useful in the treatment of non-malignant diseases of excessive cellular proliferation such as psoriasis, benign prostatic hypertrophy, atherosclerosis and restenosis.


It is disclosed in International Patent Applications WO 96/07657 & WO97/32880 that pyrimidopyrimidines are useful as inhibitors of tyrosine kinase and in particular of the EGF type receptor tyrosine kinases. Unexpectedly it was found that

-3-

pyrimidopyrimidine derivatives of the present formula (I) that are different in structure show to have tyrosine kinase inhibitory activity.

It is accordingly an object of the present invention to provide further tyrosine kinase inhibitors useful in the manufacture of medicaments in the treatment of cell proliferative related disorders.

This invention concerns compounds of formula (I)



the *N*-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein

15 $a^1 \cdot a^2 = a^3 \cdot a^4$ represents a divalent radical selected from N-CH=CH-CH, N-CH=N-CH or CH-CH=N-CH;

Z represents O, NH or S;

Y represents -C₃₋₉alkyl-, -C₃₋₉alkenyl-, -C₁₋₅alkyl-oxy-C₁₋₅alkyl-,

20 -C₁₋₅alkyl-NR¹³-C₁₋₅alkyl-, -C₁₋₅alkyl-NR¹⁴-CO-C₁₋₅alkyl-,
 -C₁₋₅alkyl-CO-NR¹⁵-C₁₋₅alkyl-, -C₁₋₆alkyl-CO-NH-,
 -C₁₋₆alkyl-NH-CO-, -CO-NH-C₁₋₆alkyl-, -NH-CO-C₁₋₆alkyl-, -CO-C₁₋₇alkyl-,
 -C₁₋₇alkyl-CO-, C₁₋₆alkyl-CO-C₁₋₆alkyl;

X¹ represents a direct bond, O, -O-C₁₋₂alkyl-, CO, -CO-C₁₋₂alkyl-, NR¹¹, -NR¹¹-C₁₋₂alkyl-, NR¹⁶-CO-, NR¹⁶-CO-C₁₋₂alkyl-, -O-N=CH- or C₁₋₂alkyl;

25 **X²** represents a direct bond, O, -O-C₁₋₂alkyl-, CO, -CO-C₁₋₂alkyl-, NR¹²,
NR¹²-C₁₋₂alkyl-, NR¹⁷-CO-, NR¹⁷-CO-C₁₋₂alkyl-, Het²⁰-C₁₋₂alkyl-, -O-N=CH- or
C₁₋₂alkyl;

R¹ represents hydrogen, cyano, halo, hydroxy, formyl, C₁₋₆alkoxy-, C₁₋₆alkyl-, C₁₋₆alkoxy- substituted with halo,

-4-

- C₁₋₄alkyl substituted with one or where possible two or more substituents selected from hydroxy or halo;
- R² represents hydrogen, cyano, halo, hydroxy, hydroxycarbonyl-, Het¹⁶-carbonyl-, C₁₋₄alkyloxy-carbonyl-, C₁₋₄alkyl-carbonyl-, aminocarbonyl-, mono- or di(C₁₋₄alkyl)aminocarbonyl-, Het¹, formyl, C₁₋₄alkyl-, C₂₋₆alkynyl-, C₃₋₆cycloalkyl-, C₃₋₆cycloalkyloxy-, C₁₋₆alkoxy-, Ar⁵, Ar¹-oxy-, dihydroxyborane, C₁₋₆alkoxy- substituted with halo, C₁₋₄alkyl substituted with one or where possible two or more substituents selected from halo, hydroxy or NR⁵R⁶,
- C₁₋₄alkyl-carbonyl- wherein said C₁₋₄alkyl is optionally substituted with one or where possible two or more substituents selected from hydroxy or C₁₋₄alkyl-oxy-;
- R³ represents hydrogen, C₁₋₄alkyl, cyano or C₁₋₄alkyl substituted with one or more substituents selected from halo, C₁₋₄alkyloxy-, amino-, mono- or di(C₁₋₄alkyl)amino-, C₁₋₄alkyl-sulfonyl- or phenyl;
- R⁴ represents hydrogen, hydroxy, Ar³-oxy, Ar⁴-C₁₋₄alkyloxy-, C₁₋₄alkyloxy-, C₂₋₄alkenyloxy- optionally substituted with Het¹² or R⁴ represents C₁₋₄alkyloxy substituted with one or where possible two or more substituents selected from C₁₋₄alkyloxy-, hydroxy, halo, Het²-, -NR⁷R⁸-, -carbonyl- NR⁹R¹⁰ or Het³-carbonyl-;
- R⁵ and R⁶ are each independently selected from hydrogen or C₁₋₄alkyl;
- R⁷ and R⁸ are each independently selected from hydrogen, C₁₋₄alkyl, Het⁸, aminosulfonyl-, mono- or di (C₁₋₄alkyl)-aminosulfonyl, hydroxy-C₁₋₄alkyl-, C₁₋₄alkyl-oxy-C₁₋₄alkyl-, hydroxycarbonyl-C₁₋₄alkyl-, C₃₋₆cycloalkyl, Het⁹-carbonyl-C₁₋₄alkyl-, Het¹⁰-carbonyl-, polyhydroxy-C₁₋₄alkyl-, Het¹¹-C₁₋₄alkyl- or Ar²-C₁₋₄alkyl-;
- R⁹ and R¹⁰ are each independently selected from hydrogen, C₁₋₄alkyl, C₃₋₆cycloalkyl, Het⁴, hydroxy-C₁₋₄alkyl-, C₁₋₄alkyloxy-C₁₋₄alkyl- or polyhydroxy-C₁₋₄alkyl-;
- R¹¹ represents hydrogen, C₁₋₄alkyl, Het⁵, Het⁶-C₁₋₄alkyl-, C₂₋₄alkenylcarbonyl- optionally substituted with Het⁷-C₁₋₄alkylaminocarbonyl-, C₂₋₄alkenylsulfonyl-, C₁₋₄alkyloxy-C₁₋₄alkyl- or phenyl optionally substituted with one or where possible two or more substituents selected from hydrogen, hydroxy, amino or C₁₋₄alkyloxy-;
- R¹² represents hydrogen, C₁₋₄alkyl, C₁₋₄alkyl-oxy-carbonyl-, Het¹⁷, Het¹⁸-C₁₋₄alkyl-, C₂₋₄alkenylcarbonyl- optionally substituted with Het¹⁹-C₁₋₄alkylaminocarbonyl-, C₂₋₄alkenylsulfonyl-, C₁₋₄alkyloxy-C₁₋₄alkyl- or phenyl optionally substituted with one or where possible two or more substituents selected from hydrogen, hydroxy, amino or C₁₋₄alkyloxy-;


-5-

- R¹³ represents hydrogen, C₁₋₄alkyl, Het¹³, Het¹⁴-C₁₋₄alkyl- or phenyl optionally substituted with one or where possible two or more substituents selected from hydrogen, hydroxy, amino or C₁₋₄alkyloxy-;
- R¹⁴ and R¹⁵ are each independently selected from hydrogen, C₁₋₄alkyl, Het¹⁵-C₁₋₄alkyl- or C₁₋₄alkyloxyC₁₋₄alkyl-;
- R¹⁶ and R¹⁷ are each independently selected from hydrogen, C₁₋₄alkyl, Het²¹-C₁₋₄alkyl- or C₁₋₄alkyloxyC₁₋₄alkyl-;
- Het¹ represents a heterocycle selected from piperidinyl, morpholinyl, piperazinyl, furanyl, pyrazolyl, dioxolanyl, thiazolyl, oxazolyl, imidazolyl, isoxazolyl, oxadiazolyl, pyridinyl or pyrrolidinyl wherein said Het¹ is optionally substituted with one or where possible two or more substituents selected from amino, C₁₋₄alkyl, hydroxy-C₁₋₄alkyl-, phenyl, phenyl-C₁₋₄alkyl-, C₁₋₄alkyl-oxy-C₁₋₄alkyl- mono- or di(C₁₋₄alkyl)amino- or amino-carbonyl-;
- Het² represents a heterocycle selected from morpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, thiomorpholinyl or dithianyl wherein said Het² is optionally substituted with one or where possible two or more substituents selected from hydroxy, halo, amino, C₁₋₄alkyl-, hydroxy-C₁₋₄alkyl-, C₁₋₄alkyl-oxy-C₁₋₄alkyl-, hydroxy-C₁₋₄alkyl-oxy-C₁₋₄alkyl-, mono- or di(C₁₋₄alkyl)amino-, mono- or di(C₁₋₄alkyl)amino-C₁₋₄alkyl-, aminoC₁₋₄alkyl-, mono- or di(C₁₋₄alkyl)amino-sulfonyl-, aminosulfonyl-;
- Het³, Het⁴ and Het⁸ each independently represent a heterocycle selected from morpholinyl, piperazinyl, piperidinyl, furanyl, pyrazolyl, dioxolanyl, thiazolyl, oxazolyl, imidazolyl, isoxazolyl, oxadiazolyl, pyridinyl or pyrrolidinyl wherein said Het³, Het⁴ or Het⁸ is optionally substituted with one or where possible two or more substituents selected from hydroxy-, amino-, C₁₋₄alkyl-, C₃₋₆cycloalkyl-C₁₋₄alkyl-, aminosulfonyl-, mono- or di(C₁₋₄alkyl)aminosulfonyl or amino-C₁₋₄alkyl-;
- Het⁵ represent a heterocycle selected from pyrrolidinyl or piperidinyl wherein said heterocycle is optionally substituted with one or where possible two or more substituents selected from C₁₋₄alkyl, C₃₋₆cycloalkyl, hydroxy-C₁₋₄alkyl-, C₁₋₄alkyloxyC₁₋₄alkyl or polyhydroxy-C₁₋₄alkyl-;
- Het⁶ and Het⁷ each independently represent a heterocycle selected from morpholinyl, pyrrolidinyl, piperazinyl or piperidinyl wherein said Het⁶ or Het⁷ is optionally substituted with one or where possible two or more substituents selected from C₁₋₄alkyl, C₃₋₆cycloalkyl, hydroxy-C₁₋₄alkyl-, C₁₋₄alkyloxyC₁₋₄alkyl or polyhydroxy-C₁₋₄alkyl-;

-6-

Het⁹ and Het¹⁰ each independently represent a heterocycle selected from furanyl, piperidinyl, morpholinyl, piperazinyl, pyrazolyl, dioxolanyl, thiazolyl, oxazolyl, imidazolyl, isoxazolyl, oxadiazolyl, pyridinyl or pyrrolidinyl wherein said Het⁹ or Het¹⁰ is optionally substituted C₁₋₄alkyl, C₃₋₆cycloalkyl-C₁₋₄alkyl- or amino-C₁₋₄alkyl-;

5



Het¹¹ represents a heterocycle selected from indolyl or

Het¹² represents a heterocycle selected from morpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, thiomorpholinyl or dithianyl wherein said Het¹² is optionally substituted with one or where possible two or more substituents selected from hydroxy, halo, amino, C₁₋₄alkyl-, hydroxy-C₁₋₄alkyl-, C₁₋₄alkyl-oxy-C₁₋₄alkyl-, hydroxy-C₁₋₄alkyl-oxy-C₁₋₄alkyl-, mono- or di(C₁₋₄alkyl)amino- or mono- or di(C₁₋₄alkyl)amino-C₁₋₄alkyl-;

10

Het¹³ represent a heterocycle selected from pyrrolidinyl or piperidinyl wherein said heterocycle is optionally substituted with one or where possible two or more substituents selected from C₁₋₄alkyl, C₃₋₆cycloalkyl, hydroxy-C₁₋₄alkyl-, C₁₋₄alkyloxyC₁₋₄alkyl or polyhydroxy-C₁₋₄alkyl-;

15

Het¹⁴ represent a heterocycle selected from morpholinyl, pyrrolidinyl, piperazinyl or piperidinyl wherein said heterocycle is optionally substituted with one or where possible two or more substituents selected from C₁₋₄alkyl, C₃₋₆cycloalkyl, hydroxy-C₁₋₄alkyl-, C₁₋₄alkyloxyC₁₋₄alkyl or polyhydroxy-C₁₋₄alkyl-;

20

Het¹⁵ and Het²¹ each independently represent a heterocycle selected from morpholinyl, pyrrolidinyl, piperazinyl or piperidinyl wherein said Het¹⁵ or Het²¹ are optionally substituted with one or where possible two or more substituents selected from C₁₋₄alkyl, C₃₋₆cycloalkyl, hydroxy-C₁₋₄alkyl-, C₁₋₄alkyloxyC₁₋₄alkyl or polyhydroxy-C₁₋₄alkyl-;

25

Het¹⁶ represent a heterocycle selected from morpholinyl, pyrrolidinyl, piperazinyl, 1,3,2-dioxaborolane or piperidinyl wherein said heterocycle is optionally substituted with one or more substituents selected from C₁₋₄alkyl;

Het¹⁷ represent a heterocycle selected from pyrrolidinyl or piperidinyl wherein said heterocycle is optionally substituted with one or where possible two or more substituents selected from C₁₋₄alkyl, C₃₋₆cycloalkyl, hydroxy-C₁₋₄alkyl-, C₁₋₄alkyloxyC₁₋₄alkyl or polyhydroxy-C₁₋₄alkyl-;

30

Het¹⁸ and Het¹⁹ each independently represent a heterocycle selected from morpholinyl, pyrrolidinyl, piperazinyl or piperidinyl wherein said Het¹⁸ and Het¹⁹ are optionally substituted with one or where possible two or more substituents selected from

35

-7-

C₁₋₄alkyl, C₃₋₆cycloalkyl, hydroxy-C₁₋₄alkyl-, C₁₋₄alkyloxyC₁₋₄alkyl or polyhydroxy-C₁₋₄alkyl-;

Het²⁰ represents a heterocycle selected from pyrrolidinyl, 2-pyrrolidinyl, piperidinyl, piperazinyl or pyrazolidinyl wherein said heterocycle is optionally substituted with one or where possible two or more substituents selected from C₁₋₄alkyl, C₃₋₆cycloalkyl, hydroxy-C₁₋₄alkyl-, C₁₋₄alkyloxyC₁₋₄alkyl or polyhydroxy-C₁₋₄alkyl-; and

Ar¹, Ar², Ar³, Ar⁴ and Ar⁵ each independently represent phenyl optionally substituted with cyano, C₁₋₄alkylsulfonyl-, C₁₋₄alkylsulfonylamino-, aminosulfonylamino-, hydroxy-C₁₋₄alkyl, aminosulfonyl-, hydroxy-, C₁₋₄alkyloxy- or C₁₋₄alkyl.

As used in the foregoing definitions and hereinafter,

- halo is generic to fluoro, chloro, bromo and iodo;

- C₁₋₂alkyl defines methyl or ethyl;

- C₁₋₃alkyl defines straight and branched chain saturated hydrocarbon radicals having from 1 to 3 carbon atoms such as, for example, methyl, ethyl, propyl and the like;

- C₁₋₄alkyl defines straight and branched chain saturated hydrocarbon radicals having from 1 to 4 carbon atoms such as, for example, methyl, ethyl, propyl, butyl, 1-

methylethyl, 2-methylpropyl, 2,2-dimethylethyl and the like;

- C₁₋₅alkyl defines straight and branched chain saturated hydrocarbon radicals having from 1 to 5 carbon atoms such as, for example, methyl, ethyl, propyl, butyl, pentyl, 1-methylbutyl, 2,2-dimethylpropyl, 2,2-dimethylethyl and the like;

- C₁₋₆alkyl is meant to include C₁₋₅alkyl and the higher homologues thereof having 6 carbon atoms such as, for example hexyl, 1,2-dimethylbutyl, 2-methylpentyl and the like;

- C₁₋₇alkyl is meant to include C₁₋₆alkyl and the higher homologues thereof having 7 carbon atoms such as, for example 1,2,3-dimethylbutyl, 1,2-methylpentyl and the like;

- C₃₋₉alkyl defines straight and branched chain saturated hydrocarbon radicals having from 3 to 9 carbon atoms such as propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl and the like;

- C₂₋₄alkenyl defines straight and branched chain hydrocarbon radicals containing one double bond and having from 2 to 4 carbon atoms such as, for example vinyl, 2-propenyl, 3-butenyl, 2-butenyl and the like;

- C₃₋₉alkenyl defines straight and branched chain hydrocarbon radicals containing one double bond and having from 3 to 9 carbon atoms such as, for example 2-propenyl, 3-butenyl, 2-butenyl, 2-pentenyl, 3-pentenyl, 3-methyl-2-butenyl, 3-hexenyl and the like;

-8-

- C₂₋₆alkynyl defines straight and branched chain hydrocarbon radicals containing one triple bond and having from 2 to 6 carbon atoms such as, for example, 2-propynyl, 3-butynyl, 2-butylnyl, 2-pentynyl, 3-pentynyl, 3-methyl-2-butylnyl, 3-hexynyl and the like;
- C₃₋₆cycloalkyl is generic to cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl;
- 5 - C₁₋₄alkyloxy defines straight or branched saturated hydrocarbon radicals such as methoxy, ethoxy, propyloxy, butyloxy, 1-methylethyloxy, 2-methylpropyloxy and the like;
- C₁₋₆alkyloxy is meant to include C₁₋₄alkyloxy and the higher homologues such as methoxy, ethoxy, propyloxy, butyloxy, 1-methylethyloxy, 2-methylpropyloxy and the like;
- 10 - polyhydroxy-C₁₋₄alkyl is generic to a C₁₋₄alkyl as defined hereinbefore, having two, three or were possible more hydroxy substituents, such as for example trifluoromethyl.

As used in the foregoing definitions and hereinafter, the term formyl refers to a radical of formula $-\text{CH}(=\text{O})$. When X¹ or X² represents the divalent radical $-\text{O}-\text{N}=\text{CH}-$, said radical is attached with the carbon atom to the R³, R⁴ bearing cyclic moiety, respectively the R¹, R² bearing phenyl moiety of the compounds of formula (I).

The heterocycles as mentioned in the above definitions and hereinafter, are meant to include all possible isomeric forms thereof, for instance pyrrolyl also includes 2*H*-pyrrolyl; triazolyl includes 1,2,4-triazolyl and 1,3,4-triazolyl; oxadiazolyl includes 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl and 1,3,4-oxadiazolyl; thiadiazolyl includes 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl and 1,3,4-thiadiazolyl; pyranlyl includes 2*H*-pyranlyl and 4*H*-pyranlyl.

Further, the heterocycles as mentioned in the above definitions and hereinafter may be attached to the remainder of the molecule of formula (I) through any ring carbon or heteroatom as appropriate. Thus, for example, when the heterocycle is imidazolyl, it may be a 1-imidazolyl, 2-imidazolyl, 3-imidazolyl, 4-imidazolyl and 5-imidazolyl; when it is thiazolyl, it may be 2-thiazolyl, 4-thiazolyl and 5-thiazolyl; when it is triazolyl, it may be 1,2,4-triazol-1-yl, 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl, 1,3,4-triazol-1-yl and 1,3,4-triazol-2-yl; when it is benzothiazolyl, it may be 2-benzothiazolyl, 4-benzothiazolyl, 5-benzothiazolyl, 6-benzothiazolyl and 7-benzothiazolyl.

The pharmaceutically acceptable addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic acid addition salt forms which the compounds of formula (I) are able to form. The latter can conveniently be obtained by

-9-

treating the base form with such appropriate acid. Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid; sulfuric; nitric; phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic
5 (i.e. butane-dioic acid), maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, *p*-toluenesulfonic, cyclamic, salicylic, *p*-aminosalicylic, pamoic and the like acids.

The pharmaceutically acceptable addition salts as mentioned hereinabove are meant to
10 comprise the therapeutically active non-toxic base addition salt forms which the compounds of formula (I) are able to form. Examples of such base addition salt forms are, for example, the sodium, potassium, calcium salts, and also the salts with pharmaceutically acceptable amines such as, for example, ammonia, alkylamines, benzathine, *N*-methyl-D-glucamine, hydrabamine, amino acids, e.g. arginine, lysine.

15 Conversely said salt forms can be converted by treatment with an appropriate base or acid into the free acid or base form.

The term addition salt as used hereinabove also comprises the solvates which the
20 compounds of formula (I) as well as the salts thereof, are able to form. Such solvates are for example hydrates, alcoholates and the like.

The term stereochemically isomeric forms as used hereinbefore defines the possible
different isomeric as well as conformational forms which the compounds of formula (I)
25 may possess. Unless otherwise mentioned or indicated, the chemical designation of compounds denotes the mixture of all possible stereochemically and conformationally isomeric forms, said mixtures containing all diastereomers, enantiomers and/or conformers of the basic molecular structure. All stereochemically isomeric forms of the compounds of formula (I) both in pure form or in admixture with each other are
30 intended to be embraced within the scope of the present invention.

Some of the compounds of formula (I) may also exist in their tautomeric forms. Such
forms although not explicitly indicated in the above formula are intended to be
included within the scope of the present invention.

35 The *N*-oxide forms of the compounds of formula (I) are meant to comprise those compounds of formula (I) wherein one or several nitrogen atoms are oxidized to the so-called *N*-oxide.

A preferred group of compounds consists of those compounds of formula (I) wherein one or more of the following restrictions apply :

Z represents NH;

- 5 Y represents -C₃₋₉alkyl-, -C₂₋₉alkenyl-, -C₁₋₅alkyl-oxy-C₁₋₅alkyl-,
-C₁₋₅alkyl-NR¹³-C₁₋₅alkyl-, -C₁₋₆alkyl-NH-CO-, -CO-C₁₋₇alkyl-, -C₁₋₇alkyl-CO- or
C₁₋₆alkyl-CO-C₁₋₆alkyl;

X¹ represents O, -O-C₁₋₂alkyl-, -O-N=CH-, NR¹¹ or -NR¹¹-C₁₋₂alkyl-; in a particular
embodiment X¹ represents -NR¹¹-, -O- or -O-CH₂-;

- 10 X² represents a direct bond, O, -O-C₁₋₂alkyl-, -O-N=CH-, C₁₋₂alkyl, NR¹² or
NR¹²-C₁₋₂alkyl-; in a particular embodiment X² represents a direct bond,
-O-N=CH-, C₁₋₂alkyl-, -O-C₁₋₂alkyl-, -O- or -O-CH₂-;

R¹ represents hydrogen, cyano, halo or hydroxy, preferably halo;

R² represents hydrogen, cyano, halo, hydroxy, hydroxycarbonyl-,

- 15 C₁₋₄alkyloxycarbonyl-, Het¹⁶-carbonyl-, C₁₋₄alkyl-, C₂₋₆alkynyl-, Ar⁵ or Het¹;
In a further embodiment R² represents hydrogen, cyano, halo, hydroxy,
or Ar⁵;

R³ represents hydrogen;

R⁴ represents hydrogen, hydroxy, C₁₋₄alkyloxy-, Ar⁴-C₁₋₄alkyloxy or R⁴ represents

- 20 C₁₋₄alkyloxy substituted with one or where possible two or more substituents
selected from
C₁₋₄alkyloxy- or Het²-;

R¹¹ represents hydrogen, C₁₋₄alkyl- or C₁₋₄alkyl-oxy-carbonyl-;

R¹² represents hydrogen, C₁₋₄alkyl- or C₁₋₄alkyl-oxy-carbonyl-;

- 25 R¹³ represents Het¹⁴-C₁₋₄alkyl, in particular morpholinyl-C₁₋₄alkyl;

Het¹ represents thiazolyl optionally substituted with amino, C₁₋₄alkyl,
hydroxy-C₁₋₄alkyl-, phenyl, phenyl-C₁₋₄alkyl-, C₁₋₄alkyl-oxy-C₁₋₄alkyl-,
mono- or di(C₁₋₄alkyl)amino- or amino-carbonyl-;

- 30 Het² represents a heterocycle selected from morpholinyl, piperazinyl, piperidinyl or
pyrrolidinyl wherein said Het² is optionally substituted with one or where possible
two or more substituents selected from hydroxy, amino or C₁₋₄alkyl-;

In a further embodiment Het² represents a heterocycle selected from morpholinyl
or piperidinyl optionally substituted with C₁₋₄alkyl-, preferably methyl;

- 35 Het¹⁴ represents a heterocycle selected from morpholinyl, piperazinyl, piperidinyl or
pyrrolidinyl wherein said Het¹⁴ is optionally substituted with one or where possible
two or more substituents selected from hydroxy, amino or C₁₋₄alkyl-;

Het¹⁶ represents a heterocycle selected from piperidinyl, morpholinyl or pyrrolidinyl;

-11-

Ar⁴ represents phenyl optionally substituted with cyano, hydroxy-, C₁₋₄alkyloxy or C₁₋₄alkyl;

Ar⁵ represents phenyl optionally substituted with cyano, hydroxy, C₁₋₄alkyloxy or C₁₋₄alkyl.

5

A further group of compounds consists of those compounds of formula (I) wherein one or more of the following restrictions apply :

Z represents NH;

Y represents -C₃₋₉alkyl-, -C₁₋₅alkyl-NR¹³-C₁₋₅alkyl-, -C₁₋₆alkyl-NH-CO- or -CO-NH -C₁₋₆alkyl- ;

10

X¹ represents -O- or -NR¹¹-;

X² represents a direct bond, -C₁₋₂alkyl-, -O-C₁₋₂alkyl-, -O- or -O-CH₂-;

R¹ represents hydrogen or halo;

R² represents hydrogen, cyano, halo, hydroxycarbonyl-, C₁₋₄alkyloxycarbonyl-,

15

Het¹⁶-carbonyl- or Ar⁵;

R³ represents hydrogen;

R⁴ represents hydrogen, hydroxy, C₁₋₄alkyloxy-, Ar⁴-C₁₋₄alkyloxy or R⁴ represents C₁₋₄alkyloxy substituted with one or where possible two or more substituents selected from

20

C₁₋₄alkyloxy- or Het²-;

R¹¹ represents hydrogen;

R¹² represents hydrogen, C₁₋₄alkyl- or C₁₋₄alkyl-oxy-carbonyl-;

R¹³ represents Het¹⁴-C₁₋₄alkyl, in particular morpholinyl-C₁₋₄alkyl;

Het² represents a heterocycle selected from morpholinyl, piperazinyl, piperidinyl or

25

pyrrolidinyl wherein said Het² is optionally substituted with one or where possible two or more substituents selected from hydroxy, amino or C₁₋₄alkyl-;

In a further embodiment Het² represents a heterocycle selected from morpholinyl or piperidinyl optionally substituted with C₁₋₄alkyl-, preferably methyl;

Het¹⁴ represents morpholinyl;

30

Het¹⁶ represents a heterocycle selected from morpholinyl or pyrrolidinyl;

Ar⁴ represents phenyl;

Ar⁵ represents phenyl optionally substituted with cyano.

Another group of compounds consists of those compounds of formula (I) wherein one or more of the following restrictions apply :

35

Z represents NH;

-12-

- Y represents -C₃₋₉alkyl-, -C₂₋₉alkenyl-, -C₁₋₅alkyl-oxy-C₁₋₅alkyl-,
 -C₁₋₅alkyl-NR¹³-C₁₋₅alkyl-, -C₁₋₅alkyl-NR¹⁴-CO-C₁₋₅alkyl-, -C₁₋₆alkyl-NH-CO-, -
 CO-C₁₋₇alkyl-, -C₁₋₇alkyl-CO- or C₁₋₆alkyl-CO-C₁₋₆alkyl;
- X¹ represents O, -O-C₁₋₂alkyl-, -O-N=CH-, NR¹¹ or -NR¹¹-C₁₋₂alkyl-; in a particular
 5 embodiment X¹ represents a direct bond, C₁₋₂alkyl-, -O-C₁₋₂alkyl-, NR¹¹-, -O- or
 -O-CH₂-;
- X² represents a direct bond, O, -O-C₁₋₂alkyl-, -O-N=CH-, NR¹⁷-CO-,
 NR¹⁷-CO-C₁₋₂alkyl-, C₁₋₂alkyl, Het²⁰-C₁₋₂alkyl-, NR¹² or NR¹²-C₁₋₂alkyl-; in a
 particular embodiment X² represents a direct bond, C₁₋₂alkyl-, -O-C₁₋₂alkyl,
 10 NR¹⁷-CO-, NR¹⁷-CO-C₁₋₂alkyl-, Het²⁰-C₁₋₂alkyl-, -O- or -O-CH₂-;
- R¹ represents hydrogen, cyano, halo or hydroxy, preferably halo;
- R² represents hydrogen, cyano, halo, hydroxy, hydroxycarbonyl-,
 C₁₋₄alkyloxycarbonyl-, Het¹⁶-carbonyl-, C₁₋₄alkyl-, C₂₋₆alkynyl-, Ar⁵ or Het¹;
 in a further embodiment R² represents hydrogen, cyano, halo, hydroxy,
 15 or Ar⁵; in a more particular embodiment R² represents hydrogen or halo;
- R³ represents hydrogen;
- R⁴ represents hydrogen, hydroxy, C₁₋₄alkyloxy-, Ar⁴-C₁₋₄alkyloxy or R⁴ represents
 C₁₋₄alkyloxy substituted with one or where possible two or more substituents
 selected from
 20 C₁₋₄alkyloxy- or Het²-;
- R¹¹ represents hydrogen, C₁₋₄alkyl- or C₁₋₄alkyl-oxy-carbonyl-;
- R¹² represents hydrogen, C₁₋₄alkyl- or C₁₋₄alkyl-oxy-carbonyl-;
- R¹³ represents hydrogen or Het¹⁴-C₁₋₄alkyl, in particular morpholinyl-C₁₋₄alkyl;
- R¹⁴ represents hydrogen or C₁₋₄alkyl;
- 25 R¹⁷ represents hydrogen, C₁₋₄alkyl-, Het²¹-C₁₋₄alkyl or C₁₋₄alkyl-oxy-C₁₋₄alkyl; in
 particular R¹⁷ represents hydrogen or C₁₋₄alkyl;
- Het¹ represents thiazolyl optionally substituted with amino, C₁₋₄alkyl,
 hydroxy-C₁₋₄alkyl-, phenyl, phenyl-C₁₋₄alkyl-, C₁₋₄alkyl-oxy-C₁₋₄alkyl-,
 mono- or di(C₁₋₄alkyl)amino- or amino-carbonyl-;
- 30 Het² represents a heterocycle selected from morpholinyl, piperazinyl, piperidinyl or
 pyrrolidinyl wherein said Het² is optionally substituted with one or where possible
 two or more substituents selected from hydroxy, amino or C₁₋₄alkyl-;
 In a further embodiment Het² represents a heterocycle selected from morpholinyl
 or piperidinyl optionally substituted with C₁₋₄alkyl-, preferably methyl;
- 35 Het¹⁴ represents a heterocycle selected from morpholinyl, piperazinyl, piperidinyl or
 pyrrolidinyl wherein said Het¹⁴ is optionally substituted with one or where possible
 two or more substituents selected from hydroxy, amino or C₁₋₄alkyl-;

-13-

Het¹⁶ represents a heterocycle selected from piperidinyl, morpholinyl or pyrrolidinyl;
 Het²⁰ represents a heterocycle selected from pyrrolidinyl, 2-pyrrolidinyl or piperidinyl;
 Het²¹ represents a heterocycle selected from morpholinyl, piperazinyl, piperidinyl or
 pyrrolidinyl wherein said Het² is optionally substituted with one or where possible

5 two or more substituents selected from hydroxy, amino or C₁₋₄alkyl-;

Ar⁴ represents phenyl optionally substituted with cyano, hydroxy-, C₁₋₄alkyloxy or
 C₁₋₄alkyl;

Ar⁵ represents phenyl optionally substituted with cyano, hydroxy, C₁₋₄alkyloxy or
 C₁₋₄alkyl.

10

A further group of compounds consists of those compounds of formula (I) wherein one
 or more of the following restrictions apply :

Z represents NH;

Y represents -C₃₋₉alkyl-, -C₁₋₅alkyl-NR¹³-C₁₋₅alkyl-, -C₁₋₅alkyl-NR¹⁴-CO-C₁₋₅alkyl-, -

15 C₁₋₆alkyl-NH-CO- or -CO-NH-C₁₋₆alkyl- ;

X¹ represents a direct bond, -C₁₋₂alkyl-, -O-C₁₋₂alkyl-, -O-, -O-CH₂- or -NR¹¹-;

X² represents -O-, -O-C₁₋₂alkyl-, -NR¹²-, NR¹²-C₁₋₂alkyl-, -NR¹⁷-CO-, NR¹⁷-CO-C₁₋₂alkyl or Het²⁰-C₁₋₂alkyl-;

R¹ represents hydrogen or halo;

20 R² represents hydrogen, cyano, halo, hydroxycarbonyl-, C₁₋₄alkyloxycarbonyl-,
 Het¹⁶-carbonyl- or Ar⁵; in particular R² represents hydrogen or halo;

R³ represents hydrogen;

R⁴ represents hydrogen, hydroxy, C₁₋₄alkyloxy-, Ar⁴-C₁₋₄alkyloxy or R⁴ represents
 C₁₋₄alkyloxy substituted with one or where possible two or more substituents
 25 selected from C₁₋₄alkyloxy- or Het²-;

R¹¹ represents hydrogen;

R¹² represents hydrogen, C₁₋₄alkyl- or C₁₋₄alkyl-oxy-carbonyl-;

R¹³ represents hydrogen or Het¹⁴-C₁₋₄alkyl, in particular hydrogen or
 morpholinyl-C₁₋₄alkyl;

30 R¹⁴ represents hydrogen;

R¹⁷ represents hydrogen;

Het² represents a heterocycle selected from morpholinyl, piperazinyl, piperidinyl or
 pyrrolidinyl wherein said Het² is optionally substituted with one or where possible
 two or more substituents selected from hydroxy, amino or C₁₋₄alkyl-;

35 In a further embodiment Het² represents a heterocycle selected from morpholinyl
 or piperidinyl optionally substituted with C₁₋₄alkyl-, preferably methyl;

Het¹⁴ represents morpholinyl;

-14-

Het¹⁶ represents a heterocycle selected from morpholinyl or pyrrolidinyl;

Het²⁰ represents pyrrolidinyl or piperidinyl;

Ar⁴ represents phenyl;

Ar⁵ represents phenyl optionally substituted with cyano.

5

Other special group of compounds are:

- those compounds of formula (I0) wherein $a^1-a^2=a^3-a^4$ represents N-CH=CH-CH;
- those compounds of formula (I) wherein $a^1-a^2=a^3-a^4$ represents N-CH=N-CH;
- 10 - those compounds of formula (I) wherein $a^1-a^2=a^3-a^4$ represents CH-CH=N-CH;
- those compounds of formula (I) wherein -X¹- represents -O-;
- those compounds of formula (I) wherein -X¹- represents -NR¹¹-, in particular -NH-;
- those compounds of formula (I) wherein -X²- represents -NR¹⁷-CO-C₁₋₂alkyl-, in particular -NH-CO-C₁₋₂alkyl-;
- 15 - those compounds of formula (I) wherein -X²- represents -NR¹²-C₁₋₂alkyl-, in particular -NH-C₁₋₂alkyl-;
- those compounds of formula (I) wherein -Y- represents -C₁₋₅alkyl-NR¹⁴-CO-C₁₋₅alkyl-, in particular -C₁₋₅alkyl-NH-CO-C₁₋₅alkyl-;
- those compounds of formula (I) wherein R¹ is fluoro, chloro or bromo;
- 20 - those compounds of formula (I) wherein R² is fluoro, chloro or bromo;
- those compounds of formula (I) wherein R¹ and R² represent halo, in particular those compounds of formula (I) wherein R¹ represents fluoro and R² represents chloro;
- those compounds of formula (I) wherein R² is Het¹, in particular thiazolyl optionally substituted with methyl;
- 25 - those compounds of formula (I) wherein R² is C₂₋₆alkynyl-, in particular ethyl;
- those compounds of formula (I) wherein R² is Ar⁵, in particular phenyl optionally substituted with cyano;
- those compounds of formula (I) wherein R³ is cyano;
- those compounds of formula (I) wherein R⁴ represents methoxy and wherein said methoxy is at position 7 of the structure of formula (I).
- 30 - those compounds of formula (I) wherein R⁴ represents C₁₋₄alkyloxy substituted with one substituent selected from C₁₋₄alkyloxy- or Het²-, in particular propyloxy substituted with morpholinyl;
- those compounds of formula (I) wherein R¹² is hydrogen or C₁₋₄alkyl-, in particular methyl or wherein R¹² is C₁₋₄alkyl-oxy-carbonyl-, in particular t-butyl-oxy-carbonyl-
- 35

-15-

- those compounds of formula (I) wherein Het² represent morpholinyl optionally substituted with C₁₋₄alkyl, preferably morpholinyl attached through the nitrogen atom to the remainder of the compounds of formula (I);
- those compounds of formula (I) with Het³ represent morpholinyl optionally substituted with C₁₋₄alkyl, preferably morpholinyl attached through the nitrogen atom to the remainder of the compounds of formula (I);
- those compounds of formula (I) wherein Het¹² represent morpholinyl optionally substituted with C₁₋₄alkyl, preferably morpholinyl attached through the nitrogen atom to the remainder of the compounds of formula (I).

10

In a further embodiment of the present invention the R¹ substituent is at position 4', the R² substituent is at position 5', the R³ substituent is at position 2 and the R⁴ substituent at position 6 of the structure of formula (I). A particular group of compounds according to the present invention are those compounds of formula (I) wherein the aniline fragment is substituted with an R² substituent at position 5' and an R¹ substituent at position 4' and wherein said R¹ substituent represents halo, in particular fluoro and wherein said R² substituent is being selected from the group consisting of halo, C₁₋₄alkyloxycarbonyl-, Het¹⁶-carbonyl-, hydroxycarbonyl-, cyano, or Ar⁵; in particular said R² being selected from chloro, bromo, methoxycarbonyl, pyrrolidino-carbonyl, morpholino-carbonyl, hydroxycarbonyl, cyano or phenyl.

20

The compounds of this invention can be prepared by any of several standard synthetic processes commonly used by those skilled in the art of organic chemistry and described for instance in the following references; "Heterocyclic Compounds" – Vol.24 (part4) p 261-304 Fused pyrimidines, Wiley – Interscience ; Chem. Pharm. Bull., Vol 41(2) 362-368 (1993); J.Chem.Soc., Perkin Trans. 1, 2001, 130-137.

25


In brief, for those compounds of formula (I) where –X¹- represents –NH- said compounds are generally prepared by reacting the 4-chloro-6-fluoro-pyridopyrimidines or 4,6-dichloro-pyridopyrimidines of formula (II) with an appropriate aniline (III) using art known reaction conditions, such as for example using a base such as triethylamine, *N*-ethyl-*N*-(1-methylethyl)-2-propaneamine (DIPEA) and alike or an inorganic base such as Na₂CO₃, K₂CO₃ and alike in a suitable polar solvent such as propane-2-ol, 1-butanol, acetonitrile and alike at elevated temperatures (60-90°C or reflux temperatures). The thus obtained anilinopyridopyrimidens (IV) are in a further step substituted by a suitable amine of formula (VII) to give the intermediate of formula VIII. This second substitution reaction is performed under known reactions conditions,

35

-16-

such as for example, by stirring the reagentia at an elevated temperature (70-100°C) optionally in an appropriate solvent such as propane-2-ol, 1-butanol or DMSO in the presence of a base such as for example triethylamine, *N*-ethyl-*N*-(1-methylethyl)-2-propanamine (DIPEA) and alike. The compounds according to the invention are finally obtained after deprotection and ring closure using art known conditions. Ring closure is typically performed in the presence of a coupling reagent such as for example 1,3-dicyclohexylcarbodiimide (DCC), *N,N'*-carbonyldiimidazole (CDI), POCl₃, TiCl₄, sulfur chloride fluoride (SO₂ClF) or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDCI) in the presence or absence of hydroxybenzotriazole (HOBt).

Scheme 0




P_1 and P_2 each independently represent optionally protected functional groups, such as for example a primary or secondary amine, hydroxyl, hydroxycarbonyl, or halo (Cl, Br or I), which upon reaction produce together with the Y_1 respectively Y_2 substituents to which they are attached, the divalent Y radical as defined for the compounds of formula (I) hereinbefore. X^1 , X^2 , R^1 , R^2 , R^3 and R^4 are defined as for the compounds of formula (I) hereinbefore.

As further exemplified in the experimental part of the description, the group of compounds of formula (I) where $-X^1-$ represents $-O-$, hereinafter referred to as compounds of formula (I'), are generally prepared using the following synthesis scheme. The compounds of this invention may be prepared by coupling the known 4-chloro-6-chloropyrimidopyrimidine (II) with suitable substituted anilines (III), which in their turn can be prepared according to reaction schemes 3-7, furnish the intermediate compounds (IV). Substitution under art known conditions of the 6-chloro group with

-17-

an appropriate alkoxide, such as for example benzyloxide, methoxide, 2-trimethylsilylethanol, should give upon deprotection, respectively catalytic hydrogenation, TMSCl, Na₂S, TFA, the desired Mitsunobu precursor of formula (VI) (Scheme 1). Next, ring closure under Mitsunobu conditions give the target compounds (I').

Scheme 1




V = hydrogen or a protective group such as for example, methylcarbonyl, t-butyl, methyl, ethyl, benzyl or trialkylsilyl groups; R represents benzyl or methyl; and a¹-a²=a³-a⁴, Y, X², R¹, R², R³ and R⁴ are defined as for the compounds of formula (I)

Those compounds of formula (I'), where X² represents -O- and a¹-a²=a³-a⁴ represents N-C=N-C are prepared by coupling the known 8-chloro-2(methylthio)-pyrimido[5,4-d]pyrimidine (XXVII) with 2-aminophenol derivatives of formula (XXVIII) yielding the intermediate compounds of formula (XXIX). Next, after protection of the phenol and oxidation of the methylthio, the pyrimidopyrimidine of formula (VIII) is converted into the intermediate of formula (IX) using the appropriate alkoxide. Subsequent deprotection followed by ring closure under Mitsunobu conditions should give the target compounds of formula (I').

-18-

Scheme 2



V = hydrogen or a protective group such as for example, methylcarbonyl, t-butyl, methyl, ethyl, benzyl or trialkylsilyl groups; and Y, X², R¹, R², R³ and R⁴ are defined as for the compounds of formula (I)


5

Alternatively, those compounds of formula (I'), where X² represents -O- and a¹-a²=a³-a⁴ represents C=C=C-N, said compounds are prepared by coupling the known 4-chloro-6-fluoropyridopyrimidines (II) with 2-aminophenol derivatives of formula (XXVIII) yielding the intermediate compounds of formula (VII). Next, after protection of the phenol, the pyridopyrimidine of formula (VIII) is converted into the intermediate of formula (IX) using the appropriate alkoxide. Subsequent deprotection followed by ring closure under Mitsunobu conditions should give the target compounds of formula (I'').

10

-19-

Scheme 3



V = hydrogen or a protective group such as for example, methylcarbonyl, t-butyl, methyl, ethyl, benzyl or trialkylsilyl groups; and Y, R¹, R², R³ and R⁴ are defined as for the compounds of formula (I)


5

For those compounds where X² represents -O-, the suitable substituted anilines of formula (III^a) are generally prepared from the commercially available nitro-phenols (X) and the α, ω-protected halogenated alcohols (XI) under alkaline conditions in a reaction inert solvent, for example, using dimethylacetamide (DMA) in the presence of

10 K₂CO₃. The resulting nitro-phenyl derivative (XII) is subsequently reduced according to standard conditions, for example, using iron/acetic acid, to yield the substituted anilines of formula (III^a) (Scheme 4).

-20-


Scheme 4



X represents a halogen such as for example, Cl, Br and I
 V represents a protective group such as for example methylcarbonyl

- For those compounds where X² represents -NR¹²- or -NR¹²-C₁₋₂alkyl-, the suitable substituted anilines of formula (III^b) are generally prepared from the commercially available 2-nitro-benzaldehydes (XIII) and the amine substituted alcohols (XIV) by reductive amination under standard conditions, for example using NaBH₄ and titanium(iv)isopropoxide as reducing agents in ethanol as solvent, yielding in a first step the nitro-benzylamines of formula (XV).
 Next the primary free alcohol is protected using art known procedures, for example, using an esterification reaction with acetic anhydride in the presence of pyridine.
 The thus obtained intermediate of formula (XVI) is subsequently reduced according to standard conditions, for example, using iron/acetic acid to yield the substituted anilines of formula (III^b) (Scheme 5).

Scheme 5




V represents a protective group such as for example methylcarbonyl
 m = 0 or 1 and n = 1 or 2

-21-

For those compounds where X^2 represents $-O-N=CH-$, the suitable substituted anilines of formula (III^c) are generally prepared according to reaction scheme 5.

In a first step the known 2-nitro-benzaldehydes (XIII) are converted into the corresponding oxime (XVII) using, for example, the art known condensation reaction with hydroxylamine.

Next said oxime of formula XVII is allowed to react for example, with an halogenated alkylacetate under alkaline conditions, for example using K_2CO_3 in DMSO or with a stronger silyl protecting group like TBDMS or TBDPS, and NaH in THF for the reaction conditions, followed by reducing the nitro group, for example, with iron/ acetic acid, to provide the suitable substituted aniline of formula (III^c).



X represents a halogen such as for example Cl, Br or I


For those compounds where X^2 represents a direct bond and Y represents C₁₋₆alkyl-NH-CO-, the suitable substituted anilines of formula (III^d) are generally prepared according to reaction scheme 7.

In a first step the known 2-nitro-benzoic acids (XX) are amidated to the intermediates of formula (XXII) under art known conditions, for example, using a hydroxylated amine of formula (XXI) that is added dropwise to a mixture of (XX) in CH₂Cl₂ in the presence of 1,1'-carbonylbis-1H-imidazole.

Next the primary free alcohol is protected using art known procedures, for example, using an esterification reaction with acetic anhydride in the presence of pyridine. The thus obtained intermediate of formula (XXIII) is subsequently reduced according to standard conditions, for example, using iron/acetic acid to yield the substituted anilines of formula (III^d).

-22-

Scheme 7




V represents a protective group such as for example methylcarbonyl

For those compounds where X² represents a direct bond the suitable substituted anilines of formula (III^e) are generally prepared according to reaction scheme 7.

- 5 In a first step the known 2-nitro-benzaldehydes (XIII) are alkenated to the intermediates of formula (XXV) under art known conditions, for example, using the Wittig Reaction with the appropriate phosphonium salt of formula (XXIV). Following esterification of the free carboxylic acid under standard conditions for example, using ethanol under acidic conditions, the intermediate of formula (XXVI) are
- 10 reduced to yield the desired substituted anilines of formula (III^e).

Scheme 8



Y₁ represents a C₁₋₇alkyl


- As further exemplified in the experimental part of the description, the group of
- 15 compounds of formula (I) were -X¹- represents -NR¹¹- and a¹-a²=a³-a⁴ represents N-

-23-

CH=N-CH, hereinafter referred to as compounds of formula (I'''), are generally prepared using the following synthesis scheme (Scheme 9). Said compounds may be prepared by coupling the known 8-chloro-2(methylthio)-pyrimido[5,4-d]pyrimidine with 2-aminophenol derivatives of formula (XXVIII), yielding the intermediate compounds of formula (XXIX).

Next, the pyrimido[5,4-d]pyrimidine of formula (XXIX) is aminated using an aminated alcohol (XXX) under art known conditions, followed by ring closure under Mitsunobu conditions to give the target compounds of formula (I''').

Scheme 9




Alternatively, for those compounds of formula (I) where -X¹- represents -NR¹¹- and a¹-a²=a³-a⁴ represents N-CH=CH-CH, the compounds are prepared by coupling the known 4,6-dichloro- (XXVII') with 2-aminophenol derivatives of formula (XXVIII), yielding the intermediate compounds of formula (XXIX').

Next, the pyrido[3,2-d]pyrimidine of formula (XXIX') is aminated using an aminated alcohol (XXX) under art known conditions, followed by ring closure under Mitsunobu conditions to give the target compounds of formula (I''') (Scheme 10).

-24-

Scheme 10



Where necessary or desired, any one or more of the following further steps in any order may be performed :

- (i) removing any remaining protecting group(s);
- (ii) converting a compound of formula (I) or a protected form thereof into a further compound of formula (I) or a protected form thereof;
- (iii) converting a compound of formula (I) or a protected form thereof into a *N*-oxide, a salt, a quaternary amine or a solvate of a compound of formula (I) or a protected form thereof;
- (iv) converting a *N*-oxide, a salt, a quaternary amine or a solvate of a compound of formula (I) or a protected form thereof into a compound of formula (I) or a protected form thereof;
- (v) converting a *N*-oxide, a salt, a quaternary amine or a solvate of a compound of formula (I) or a protected form thereof into another *N*-oxide, a pharmaceutically acceptable addition salt a quaternary amine or a solvate of a compound of formula (I) or a protected form thereof;
- (vi) where the compound of formula (I) is obtained as a mixture of (R) and (S) enantiomers resolving the mixture to obtain the desired enantiomer.

Compounds of formula (I), *N*-oxides, addition salts, quaternary amines and stereochemical isomeric forms thereof can be converted into further compounds according to the invention using procedures known in the art.

-25-

It will be appreciated by those skilled in the art that in the processes described above the functional groups of intermediate compounds may need to be blocked by protecting groups.

- 5 Functional groups, which it is desirable to protect, include hydroxy, amino and carboxylic acid. Suitable protecting groups for hydroxy include trialkylsilyl groups (e.g. tert-butyldimethylsilyl, tert-butyldiphenylsilyl or trimethylsilyl), benzyl and tetrahydropyranyl. Suitable protecting groups for amino include tert-butoxycarbonyl or benzyloxycarbonyl. Suitable protecting groups for carboxylic acid include C₍₁₋₆₎alkyl
10 or benzyl esters.

The protection and deprotection of functional groups may take place before or after a reaction step.

- 15 Additionally, the N-atoms in compounds of formula (I) can be methylated by art-known methods using CH₃-I in a suitable solvent such as, for example 2-propanone, tetrahydrofuran or dimethylformamide.

- The compounds of formula (I) can also be converted into each other following art-known procedures of functional group transformation of which some examples are
20 mentioned hereinafter.

- The compounds of formula (I) may also be converted to the corresponding *N*-oxide forms following art-known procedures for converting a trivalent nitrogen into its
25 *N*-oxide form. Said *N*-oxidation reaction may generally be carried out by reacting the starting material of formula (I) with 3-phenyl-2-(phenylsulfonyl)oxaziridine or with an appropriate organic or inorganic peroxide. Appropriate inorganic peroxides comprise, for example, hydrogen peroxide, alkali metal or earth alkaline metal peroxides, e.g. sodium peroxide, potassium peroxide; appropriate organic peroxides may comprise
30 peroxy acids such as, for example, benzenecarboperoxoic acid or halo substituted benzenecarboperoxoic acid, e.g. 3-chlorobenzenecarboperoxoic acid, peroxyalkanoic acids, e.g. peroxyacetic acid, alkylhydroperoxides, e.g. *t*-butyl hydroperoxide. Suitable solvents are, for example, water, lower alkanols, e.g. ethanol and the like, hydrocarbons, e.g. toluene, ketones, e.g. 2-butanone, halogenated hydrocarbons, e.g.
35 dichloromethane, and mixtures of such solvents.

-26-

Pure stereochemically isomeric forms of the compounds of formula (I) may be obtained by the application of art-known procedures. Diastereomers may be separated by physical methods such as selective crystallization and chromatographic techniques, e.g. counter-current distribution, liquid chromatography and the like.

5

Some of the compounds of formula (I) and some of the intermediates in the present invention may contain an asymmetric carbon atom. Pure stereochemically isomeric forms of said compounds and said intermediates can be obtained by the application of art-known procedures. For example, diastereoisomers can be separated by physical methods such as selective crystallization or chromatographic techniques, e.g. counter current distribution, liquid chromatography and the like methods. Enantiomers can be obtained from racemic mixtures by first converting said racemic mixtures with suitable resolving agents such as, for example, chiral acids, to mixtures of diastereomeric salts or compounds; then physically separating said mixtures of diastereomeric salts or compounds by, for example, selective crystallization or chromatographic techniques, e.g. liquid chromatography and the like methods; and finally converting said separated diastereomeric salts or compounds into the corresponding enantiomers. Pure stereochemically isomeric forms may also be obtained from the pure stereochemically isomeric forms of the appropriate intermediates and starting materials, provided that the intervening reactions occur stereospecifically.


20

An alternative manner of separating the enantiomeric forms of the compounds of formula (I) and intermediates involves liquid chromatography, in particular liquid chromatography using a chiral stationary phase.

25

Some of the intermediates and starting materials as used in the reaction procedures mentioned hereinabove are known compounds and may be commercially available or may be prepared according to art-known procedures. However, in the synthesis of the compounds of formula (I), the present invention further provides the intermediates of formula (III)

30



the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein

-27-

- V represents hydrogen or a protective group preferably selected from the group consisting of methylcarbonyl, t-butyl, methyl, ethyl, benzyl or trialkylsilyl;
- Y represents -C₃₋₉alkyl-, -C₃₋₉alkenyl-, -C₁₋₅alkyl-oxy-C₁₋₅alkyl-,
 -C₁₋₅alkyl-NR¹³-C₁₋₅alkyl-, -C₁₋₅alkyl-NR¹⁴-CO-C₁₋₅alkyl-,
 5 -C₁₋₅alkyl-CO-NR¹⁵-C₁₋₅alkyl-, -C₁₋₆alkyl-CO-NH-, -C₁₋₆alkyl-NH-CO-,
 -C₁₋₇alkyl-CO-, C₁₋₆alkyl-CO-C₁₋₆alkyl;
- X² represents a direct bond, O, -O-C₁₋₂alkyl-, CO, -CO-C₁₋₂alkyl-, NR¹²,
 -NR¹²-C₁₋₂alkyl-, -CH₂-, -O-N=CH- or C₁₋₂alkyl;
- R¹ represents hydrogen, cyano, halo, hydroxy, formyl, C₁₋₆alkoxy-, C₁₋₆alkyl-,
 10 C₁₋₆alkoxy- substituted with halo,
 C₁₋₄alkyl substituted with one or where possible two or more substituents selected
 from hydroxy or halo; and
- R² represents hydrogen, cyano, halo, hydroxy, hydroxycarbonyl-, Het¹⁶-carbonyl-,
 C₁₋₄alkyloxy carbonyl-, C₁₋₄alkyl carbonyl-, aminocarbonyl-, mono-or
 15 di(C₁₋₄alkyl)aminocarbonyl-, Het¹, formyl, C₁₋₄alkyl-, C₂₋₆alkynyl-, C₃₋₆cycloalkyl-,
 C₃₋₆cycloalkyloxy-, C₁₋₆alkoxy-, Ar⁵, Ar¹-oxy-, dihydroxyborane ,
 C₁₋₆alkoxy- substituted with halo,
 C₁₋₄alkyl substituted with one or where possible two or more substituents selected
 from halo, hydroxy or NR⁵R⁶,
- 20 C₁₋₄alkyl carbonyl- wherein said C₁₋₄alkyl is optionally substituted with one or
 where possible two or more substituents selected from hydroxy or
 C₁₋₄alkyl-oxy-;
- R⁵ and R⁶ are each independently selected from hydrogen or C₁₋₄alkyl;
- R¹² represents hydrogen, C₁₋₄alkyl, C₁₋₄alkyl-oxy-carbonyl-, Het¹⁷, Het¹⁸-C₁₋₄alkyl-,
 25 C₂₋₄alkenyl carbonyl- optionally substituted with Het¹⁹-C₁₋₄alkylaminocarbonyl-,
 C₂₋₄alkenylsulfonyl-, C₁₋₄alkyloxyC₁₋₄alkyl- or phenyl optionally substituted with
 one or where possible two or more substituents selected from hydrogen, hydroxy,
 amino or C₁₋₄alkyloxy-;
- R¹³ represents hydrogen, C₁₋₄alkyl, Het¹³, Het¹⁴-C₁₋₄alkyl- or phenyl optionally
 30 substituted with one or where possible two or more substituents selected from
 hydrogen, hydroxy, amino or C₁₋₄alkyloxy-;
- R¹⁴ and R¹⁵ are each independently selected from hydrogen, C₁₋₄alkyl, Het¹⁵-C₁₋₄alkyl-
 or C₁₋₄alkyloxyC₁₋₄alkyl-;
- Het¹ represents a heterocycle selected from piperidinyl, morpholinyl, piperazinyl,
 35 furanyl, pyrazolyl, dioxolanyl, thiazolyl, oxazolyl, imidazolyl, isoxazolyl,
 oxadiazolyl, pyridinyl or pyrrolidinyl wherein said Het¹ is optionally substituted

-28-

- amino, C₁₋₄alkyl, hydroxy-C₁₋₄alkyl-, phenyl, phenyl-C₁₋₄alkyl-,
 C₁₋₄alkyl-oxy-C₁₋₄alkyl- mono- or di(C₁₋₄alkyl)amino- or amino-carbonyl-;
 Het¹³ represent a heterocycle selected from pyrrolidinyl or piperidinyl wherein said
 heterocycle is optionally substituted with one or where possible two or more
 5 substituents selected from C₁₋₄alkyl, C₃₋₆cycloalkyl, hydroxy-C₁₋₄alkyl-,
 C₁₋₄alkyloxyC₁₋₄alkyl or polyhydroxy-C₁₋₄alkyl-;
 Het¹⁴ represent a heterocycle selected from morpholinyl, pyrrolidinyl, piperazinyl or
 piperidinyl wherein said heterocycle is optionally substituted with one or where
 possible two or more substituents selected from C₁₋₄alkyl, C₃₋₆cycloalkyl,
 10 hydroxy-C₁₋₄alkyl-, C₁₋₄alkyloxyC₁₋₄alkyl or polyhydroxy-C₁₋₄alkyl-;
 Het¹⁵ represent a heterocycle selected from morpholinyl, pyrrolidinyl, piperazinyl or
 piperidinyl wherein said heterocycle is optionally substituted with one or where
 possible two or more substituents selected from C₁₋₄alkyl, C₃₋₆cycloalkyl,
 hydroxy-C₁₋₄alkyl-, C₁₋₄alkyloxyC₁₋₄alkyl or polyhydroxy-C₁₋₄alkyl-;
 15 Het¹⁶ represent a heterocycle selected from morpholinyl, pyrrolidinyl, piperazinyl,
 1,3,2-dioxaborolane or piperidinyl wherein said heterocycle is optionally
 substituted with one or more substituents selected from C₁₋₄alkyl; and
 Het¹⁷ represent a heterocycle selected from pyrrolidinyl or piperidinyl wherein said
 heterocycle is optionally substituted with one or where possible two or more
 20 substituents selected from C₁₋₄alkyl, C₃₋₆cycloalkyl, hydroxy-C₁₋₄alkyl-, C₁₋₄-
 alkyloxyC₁₋₄alkyl or polyhydroxy-C₁₋₄alkyl-;
 Het¹⁸ and Het¹⁹ each independently represent a heterocycle selected from morpholinyl,
 pyrrolidinyl, piperazinyl or piperidinyl wherein said Het¹⁸ and Het¹⁹ are optionally
 substituted with one or where possible two or more substituents selected from
 25 C₁₋₄alkyl, C₃₋₆cycloalkyl, hydroxy-C₁₋₄alkyl-, C₁₋₄alkyloxyC₁₋₄alkyl or
 polyhydroxy-C₁₋₄alkyl-;
 Ar¹, Ar², Ar³, Ar⁴ and Ar⁵ each independently represent phenyl optionally substituted
 with cyano, C₁₋₄alkylsulfonyl-, C₁₋₄alkylsulfonylamino-, aminosulfonylamino-,
 hydroxy-C₁₋₄alkyl, aminosulfonyl-, hydroxy-, C₁₋₄alkyloxy- or C₁₋₄alkyl.
 30
- In particular the intermediates of formula (III) wherein one or more of the following
 restrictions apply;
- i) Y represents -C₃₋₉alkyl-, -C₁₋₅alkyl-oxy-C₁₋₅alkyl-, -C₁₋₅alkyl-NR¹³-C₁₋₅alkyl-,
 -C₁₋₆alkyl-NH-CO-;
 - 35 ii) X² represents a direct bond, O, -O-C₁₋₂alkyl-, NR¹²-, -NR¹²-C₁₋₂alkyl-, -CH₂-,
 -O-N=CH- or C₁₋₂alkyl;
 - iii) R¹ represents hydrogen, cyano, halo or hydroxy, preferably halo;

-29-


- iv) R^2 represents hydrogen, cyano, halo, hydroxy, hydroxycarbonyl-,
 C_{1-4} alkyloxycarbonyl-, Het^{16} -carbonyl-, C_{1-4} alkyl-, C_{2-6} alkynyl-, Ar^5 or Het^1 ;
 In a further embodiment R^2 represents hydrogen, cyano, halo, hydroxy,
 C_{2-6} alkynyl- or Het^1 ; in particular R^2 represents hydrogen, cyano, halo, hydroxy, or
 Ar^5 ;
 v) R^{12} represents hydrogen, C_{1-4} alkyl, or C_{1-4} alkyloxycarbonyl;
 vi) R^{13} represents Het^{14} - C_{1-4} alkyl, in particular morpholinyl- C_{1-4} alkyl;
 vii) Het^1 represents thiazolyl optionally substituted with amino, C_{1-4} alkyl,
 hydroxy- C_{1-4} alkyl-, phenyl, phenyl- C_{1-4} alkyl-, C_{1-4} alkyl-oxy- C_{1-4} alkyl-, mono- or
 di(C_{1-4} alkyl)amino- or amino-carbonyl-;
 viii) Het^{16} represents a heterocycle selected from piperidinyl or pyrrolidinyl.

It is also an object of the present invention to provide the use of an intermediate of
 formula (III) in the synthesis of a macrocyclic kinase inhibitor such as for example
 compound of formula (I).

The compounds of formula (I) and the intermediates of formula (XXXI) of the present
 invention are useful because they possess pharmacological properties. They can
 therefore be used as medicines.

20

Accordingly, in a further aspect this invention concerns the intermediates of formula
 (XXXI)



- the N-oxide forms, the pharmaceutically acceptable addition salts and the
 stereochemically isomeric forms thereof, wherein
 $a^1-a^2=a^3-a^4$ represents a divalent radical selected from $N-CH=CH-CH$ or $N-CH=N-CH$;
 Y represents $-C_{3-9}$ alkyl-, $-C_{1-5}$ alkyl- NR^{13} - C_{1-5} alkyl-, $-C_{1-6}$ alkyl-NH-CO- or
 $-CO-NH-C_{1-6}$ alkyl- ;
 R^1 represents hydrogen or halo;
 R^2 represents hydrogen, cyano, halo, hydroxycarbonyl-, C_{1-4} alkyloxycarbonyl-,
 Het^{16} -carbonyl- or Ar^5 ;

30

-30-

- R⁴ represents hydroxy, C₁₋₄alkyloxy-, Ar⁴-C₁₋₄alkyloxy or R⁴ represents C₁₋₄alkyloxy substituted with one or where possible two or more substituents selected from C₁₋₄alkyloxy- or Het²-;
- R¹¹ represents hydrogen;
- 5 R¹³ represents Het¹⁴-C₁₋₄alkyl, in particular morpholinyl-C₁₋₄alkyl;
- Het² represents a heterocycle selected from morpholinyl, piperazinyl, piperidinyl or pyrrolidinyl wherein said Het² is optionally substituted with one or where possible two or more substituents selected from hydroxy, amino or C₁₋₄alkyl-;
- In a further embodiment Het² represents a heterocycle selected from morpholinyl or piperidinyl optionally substituted with C₁₋₄alkyl-, preferably methyl;
- 10 Het¹⁴ represents morpholinyl;
- Het¹⁶ represents a heterocycle selected from morpholinyl or pyrrolidinyl;
- Ar⁴ represents phenyl;
- Ar⁵ represents phenyl optionally substituted with cyano; as well as the use of an
- 15 intermediate of formula (XXXI) in the synthesis of a macrocyclic kinase inhibitor such as for example the compounds of formula (I).

As described in the experimental part hereinafter, the growth inhibitory effect and anti-tumour activity of the present compounds and some of the intermediates has been

20 demonstrated in vitro, in enzymatic assays on the receptor tyrosine kinase EGFR. In an alternative assay, the growth inhibitory effect of the compounds was tested on the ovarian carcinoma cell line SKOV3 using art known cytotoxicity assays such as LIVE/DEAD (Molecular Probes) or MTT.

25 Accordingly, the present invention provides the compounds of formula (I) and the intermediates of formula (XXXI) and their pharmaceutically acceptable *N*-oxides, addition salts, quaternary amines and stereochemically isomeric forms for use in therapy. More particular in the treatment or prevention of cell proliferation mediated diseases. The compounds of formula (I), the intermediates of formula (XXXI) and their

30 pharmaceutically acceptable *N*-oxides, addition salts, quaternary amines and the stereochemically isomeric forms may hereinafter be referred to as compounds according to the invention.

Disorders for which the compounds according to the invention are particularly useful

35 are atherosclerosis, restenosis, cancer and diabetic complications e.g. retinopathy.

-31-

In view of the utility of the compounds according to the invention, there is provided a method of treating a cell proliferative disorder such as atherosclerosis, restenosis and cancer, the method comprising administering to an animal in need of such treatment, for example, a mammal including humans, suffering from a cell proliferative disorder,
5 a therapeutically effective amount of a compound according to the present invention.

Said method comprising the systemic or topical administration of an effective amount of a compound according to the invention, to animals, including humans. One skilled in the art will recognize that a therapeutically effective amount of the EGFR inhibitors
10 of the present invention is the amount sufficient to induce the growth inhibitory effect and that this amount varies *inter alia*, depending on the size, the type of the neoplasia, the concentration of the compound in the therapeutic formulation, and the condition of the patient. Generally, an amount of EGFR inhibitor to be administered as a therapeutic agent for treating cell proliferative disorder such as atherosclerosis,
15 restenosis and cancer, will be determined on a case by case by an attending physician.

Generally, a suitable dose is one that results in a concentration of the EGFR inhibitor at the treatment site in the range of 0.5 nM to 200 μ M, and more usually 5 nM to 10 μ M. To obtain these treatment concentrations, a patient in need of treatment likely will be
20 administered between 0.01 mg/kg to 300 mg/kg body weight, in particular from 10 mg/kg to 100 mg/kg body weight. As noted above, the above amounts may vary on a case-by-case basis. In these methods of treatment the compounds according to the invention are preferably formulated prior to admission. As described herein below, suitable pharmaceutical formulations are prepared by known procedures using well
25 known and readily available ingredients.

Due to their high degree of selectivity as EGFR inhibitors, the compounds of formula (I) and the intermediates of formula (XXXI) as defined above, are also useful to mark or identify the kinase domain within the receptor tyrosine kinase receptors. To
30 this purpose, the compounds of the present invention can be labelled, in particular by replacing, partially or completely, one or more atoms in the molecule by their radioactive isotopes. Examples of interesting labelled compounds are those compounds having at least one halo which is a radioactive isotope of iodine, bromine or fluorine; or those compounds having at least one ^{11}C -atom or tritium atom.

35 One particular group consists of those compounds of formula (I) and intermediates of formula (XXXI) wherein R^1 is a radioactive halogen atom. In principle, any compound according to the invention containing a halogen atom is prone for

-32-

radiolabelling by replacing the halogen atom by a suitable isotope. Suitable halogen radioisotopes to this purpose are radioactive iodides, e.g. ^{122}I , ^{123}I , ^{125}I , ^{131}I ; radioactive bromides, e.g. ^{75}Br , ^{76}Br , ^{77}Br and ^{82}Br , and radioactive fluorides, e.g. ^{18}F . The introduction of a radioactive halogen atom can be performed by a suitable exchange
5 reaction or by using any one of the procedures as described hereinabove to prepare halogen derivatives of formula (I).

Another interesting form of radiolabelling is by substituting a carbon atom by a ^{11}C -atom or the substitution of a hydrogen atom by a tritium atom.

Hence, said radiolabelled compounds according to the invention can be used in a
10 process of specifically marking receptor sites in biological material. Said process comprises the steps of (a) radiolabelling a compound according to the invention, (b) administering this radiolabelled compound to biological material and subsequently (c) detecting the emissions from the radiolabelled compound.

The term biological material is meant to comprise every kind of material which has
15 a biological origin. More in particular this term refers to tissue samples, plasma or body fluids but also to animals, specially warm-blooded animals, or parts of animals such as organs.

When used in *in vivo* assays, the radiolabelled compounds are administered in an appropriate composition to an animal and the location of said radiolabelled compounds
20 is detected using imaging techniques, such as, for instance, Single Photon Emission Computerized Tomography (SPECT) or Positron Emission Tomography (PET) and the like. In this manner the distribution of the particular receptor sites throughout the body can be detected and organs containing said receptor sites can be visualized by the imaging techniques mentioned hereinabove. This process of imaging an organ by
25 administering a radiolabelled compound of formula (I) and detecting the emissions from the radioactive compound also constitutes a part of the present invention.

In yet a further aspect, the present invention provides the use of the compounds according to the invention in the manufacture of a medicament for treating any of the
30 aforementioned cell proliferative disorders or indications.

The amount of a compound according to the present invention, also referred to here as the active ingredient, which is required to achieve a therapeutical effect will be, of course, vary with the particular compound, the route of administration, the age and
35 condition of the recipient, and the particular disorder or disease being treated. A suitable daily dose would be from 0.01 mg/kg to 300 mg/kg body weight, in particular from 10 mg/kg to 100 mg/kg body weight. A method of treatment may also include

-33-

administering the active ingredient on a regimen of between one and four intakes per day.

While it is possible for the active ingredient to be administered alone, it is preferable to present it as a pharmaceutical composition. Accordingly, the present invention further provides a pharmaceutical composition comprising a compound according to the present invention, together with a pharmaceutically acceptable carrier or diluent. The carrier or diluent must be "acceptable" in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipients thereof.

The pharmaceutical compositions of this invention may be prepared by any methods well known in the art of pharmacy, for example, using methods such as those described in Gennaro et al. Remington's Pharmaceutical Sciences (18th ed., Mack Publishing Company, 1990, see especially Part 8 : Pharmaceutical preparations and their Manufacture). A therapeutically effective amount of the particular compound, in base form or addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for systemic administration such as oral, percutaneous or parenteral administration; or topical administration such as via inhalation, a nose spray, eye drops or via a cream, gel, shampoo or the like. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wettable agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not cause

-34-

any significant deleterious effects on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on or as an ointment.

5

It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.

15

Experimental part

Hereinafter, the term 'ADDP' means 1,1'-(azodicarbonyl)bis- piperidine, 'DMF' means *N,N*-dimethylformamide, 'THF' means tetrahydrofuran, "DMSO" means dimethyl sulfoxide

20

A. Preparation of the intermediates

Example A1

a) Preparation of phenol, 4-chloro-2-[(6-chloropyrido[3,2-*d*]pyrimidin-4-yl)amino]- (intermediate 1)

25 A mixture of 4,6-dichloro- pyrido[3,2-*d*]pyrimidine (0.00255 mol) and 4-chloro-2-aminophenol (0.00446 mol) in isopropanol (30 ml) was stirred at 50°C for 2h30, then brought to room temperature and evaporated to dryness. The residue was taken up in ether, filtered and dried, yielding 1g (100%) of intermediate 1.

b) Preparation of phenol, 4-chloro-2-[[6-[(6-hydroxyhexyl)amino]pyrido[3,2-*d*]pyrimidin-4-yl]amino]- (intermediate 2)

30 A mixture of intermediate 1 (0.00255 mol) and 6-amino-1-hexanol (0.0255 mol) was stirred at 100°C for 3 hours, then brought to room temperature. The residue was purified by chromatography over silica gel (eluent: DCM/MeOH/NH₄OH 97/3/0.1; 70-200µm), yielding 0.71g (72%) of intermediate 2, melting point 260°C.

Example A2

Preparation of phenol, 4-chloro-2-[[6-[(4-hydroxybutyl)amino]pyrido[3,2-d]pyrimidin-4-yl]amino]- (intermediate 3)

A mixture of intermediate 1 (0.0013 mol) and 4-amino-1-butanol (0.026 mol) was stirred at 100°C for 4 hours, then brought to room temperature and hydrolyzed a saturated solution of sodium chloride. The mixture was extracted by DCM, decanted, dried over MgSO₄, filtered, and the solvent was evaporated till dryness. The residue (0.5g) was purified by column chromatography over silica gel (eluent: DCM/MeOH/NH₄OH 95/5/0.1; 70-200µm). The residue (81mg, 17%) was crystallized from acetonitrile and diethyl ether. The precipitate was filtered off and dried, yielding 69mg (15%) of intermediate 3, melting point 227°C.

Example A3

Preparation of phenol, 4-chloro-2-[[6-[(5-hydroxypentyl)amino]pyrido[3,2-d]pyrimidin-4-yl]amino]- (intermediate 4)

A mixture of intermediate 1 (0.0013 mol) and 5-amino-1-pentanol (0.0195 mol) was stirred at 100°C for 4 hours, then brought to room temperature and hydrolyzed a saturated of sodium chloride. The mixture was extracted by DCM, decanted and dried over MgSO₄, filtered, and the solvent was evaporated till dryness. The residue (0.45g) was purified by column chromatography over silica gel (eluent: DCM/MeOH/NH₄OH 95/5/0.1; 70-200µm). The residue (66mg, 14%) was crystallized from acetonitrile and diethyl ether. The precipitate was filtered off and dried, yielding 59mg (12%) of intermediate 4, melting point 240°C.

Example A4

a) Preparation of phenol, 4-chloro-2-[[6-(methylthio)pyrimido[5,4-d]pyrimidin-4-yl]amino]- (intermediate 5)

A mixture of 8-chloro-2-(methylthio)-pyrimido[5,4-d]pyrimidine (0.0047 mol) and 2-amino-4-chlorophenol (0.0094 mol) in dioxane (5 ml) was stirred at 80°C for 1 hour, then cooled to room temperature, the precipitate was filtered off, washed with water and then with diethyl ether and dried in vacuo, yielding 1.2g (80%) of intermediate 5.

b) Preparation of phenol, 4-chloro-2-[[6-[(6-hydroxyhexyl)amino]pyrimido[5,4-d]pyrimidin-4-yl]amino]- (intermediate 6)

A mixture of intermediate 1 (0.00172 mol) in 6-amino-1-hexanol (0.0022 mol) was melt at 100°C after 8 hours. The residue was purified by column chromatography over

-36-

silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 97/3/0.1; 35-70µm) yielding 0.170g of solid. Ether was added. The solid was filtered off and dried in vacuo, yielding 135mg (20%) of intermediate (6).

5 Example A5

a) Preparation of pyrido[3,2-d]pyrimidine, 4,6-dichloro- (intermediate 7)

DMF (3 drops) was added to a mixture of 6-chloro-pyrido[3,2-d]pyrimidin-4(1H)-one [171178-33-9] (0.00275 mol) and thionyl chloride (0.179 mol). The reaction mixture was stirred and refluxed (at 80°C) for 90 minutes. The solvent was evaporated. Some dichloromethane was added and the solvent was evaporated. The residue was dissolved in dichloromethane. The organic solution was washed with a saturated aqueous K₂CO₃ solution, then dried (MgSO₄), filtered and the solvent was evaporated, yielding 0.49g (89%) of intermediate (7). (HPLC: 85% P).

15

b) Preparation of 4-[2-(6-Chloro-pyrido[3,2-d]pyrimidin-4-ylamino)-phenoxy]-butyric acid ethyl ester (intermediate 8)

Intermediate (7) (0.00245 mol) was dissolved in 2-propanol (20 ml) (not very soluble). 4-(2-Aminophenoxy)butanoic acid ethyl ester (0.00416 mol) was added, followed by addition of *N,N*-diethylethanamine (0.00490 mol). The reaction mixture was stirred and refluxed overnight. Then, the reaction mixture was cooled to room temperature and the solvent was evaporated. The residue was taken up into diethyl ether. The precipitate was filtered off and dried (pump), yielding 1.48 g of fraction (1) (greenish solid, 92% P by HPLC-MS; presence of some starting material B). This fraction (1) was purified as described below.

25

The reaction was repeated.

Intermediate (7) (0.0055 mol) was dissolved in 2-propanol (40 ml) (not very soluble). 4-(2-Aminophenoxy)butanoic acid, ethyl ester (0.00935 mol) was added, followed by addition of *N,N*-diethylethanamine (0.0110 mol). The reaction mixture was stirred and refluxed overnight. Then, the reaction mixture was cooled to room temperature and the solvent was evaporated. The residue was combined with fraction (1) and subjected to flash column chromatography over silica gel (eluent: n-hexane/EtOAc 3/1). The product fractions were collected and the solvent was evaporated, yielding 3.04g of intermediate (8)(greenish solid in quantitative yield, used in next reaction step without further purification).

35

-37-

c) Preparation of 4-{2-[6-(3-tert-Butoxycarbonylamino-propylamino)-pyrido[3,2-d]pyrimidin-4-ylamino]-phenoxy}-butyric acid ethyl ester (intermediate 9)

Intermediate (8) (0.00026 mol) and (3-aminopropyl)carbamic acid 1,1-dimethylethyl ester (0.00288 mol) were mixed for 3 hours at 100°C in a closed reactor, yielding
5 fraction (1) (57% P by HPLC + 35% of the amide).

This fraction (1) was purified as described below.

The reaction was repeated.

10 Intermediate (8) (0.00026 mol) and (3-aminopropyl)carbamic acid 1,1-dimethylethyl ester (0.00288 mol) were mixed for 2.5 hours at 100°C in an open reaction flask (not in a closed reactor as described above). The mixture was combined with fraction (1). Purified by flash column chromatography over silica gel (eluent : n-hexane/EtOAc 3/1). The product fractions were collected and the solvent was evaporated, yielding
15 intermediate (9) (HPLC: 92% P).

d) Preparation of 4-{2-[6-(3-Amino-propylamino)-pyrido[3,2-d]pyrimidin-4-ylamino]-phenoxy}-butyric acid ethyl ester (intermediate 10)

Intermediate (9) (0.00019 mol) was dissolved in dichloromethane (4.00 ml). Trifluoroacetic acid (0.05192 mol) was added and the reaction mixture was stirred for 2
20 hours at room temperature. The solvent and remaining acid were evaporated in the rotary evaporator. The resultant residue (oil) was dried (high-vacuum pump), yielding intermediate (10) (HPLC: 93% P; quantitative yield; used in next reaction step, without further purification).

e) Preparation of 4-{2-[6-(3-Amino-propylamino)-pyrido[3,2-d]pyrimidin-4-ylamino]-phenoxy}-butyric acid (intermediate 11)

25 Intermediate (10) (0.00019 mol; 1 equiv) was dissolved in tetrahydrofuran (8.00 ml). Water (1.00 ml) was added. Lithium hydroxide monohydrate (0.0019 mol) was added as a solid. More Lithium hydroxide monohydrate was added until a basic pH was reached (until then it was acidic because of CF₃COOH remainders). The reaction mixture was stirred for 2 days at 65°C. The solvent was evaporated in the rotary
30 evaporator, yielding intermediate (11) (HPLC: 78% P; quantitative yield; used in next reaction step, without further purification).

-38-

Example A6

a) Preparation of 4-chloro-6-fluoro-pyrido[3,4-d]pyrimidine, (intermediate 12)

DMF (5 drops) was added to a mixture of 6-Fluoro-3H-pyrido[3,4-d]pyrimidin-4-one (0.00605 mol) and thionyl chloride (0.39 mol). The reaction mixture was stirred and refluxed (at 80°C) for 7 hours. The solvent was evaporated, yielding 1.254 g of intermediate (12) (impure quantitative yield; used in next reaction step, without further purification).

b) Preparation of 4-[2-(6-Fluoro-pyrido[3,4-d]pyrimidin-4-ylamino)-phenoxy]-butyric acid ethyl ester (intermediate 13)

Intermediate (12) (0.00605 mol) was dissolved in 2-propanol (40 ml). 4-(2-aminophenoxy)-butanoic acid, ethyl ester [112290-16-1] hydrochloride (0.01028 mol) was added, followed by addition of *N,N*-diethylethanamine (0.01210 mol). The reaction mixture was stirred and refluxed overnight. Then, the reaction mixture was cooled to room temperature and the solvent was evaporated. The residue was purified by flash column chromatography over silica gel (eluent : n-hexane/EtOAc 3/1). The product fractions were collected and the solvent was evaporated, yielding 0.922 g of intermediate (13) (41% yield over two steps; yellowish solid; 97% P by HPLC).

c) Preparation of 4-{2-[6-(3-tert-Butoxycarbonylamino-propylamino)-pyrido[3,4-d]pyrimidin-4-ylamino]-phenoxy}-butyric acid ethyl ester (intermediate 14)

Intermediate (13) (0.00027 mol) was dissolved in DMSO (q.s.), in a reactor. (3-Aminopropyl)carbamic acid 1,1-dimethylethyl ester [75178-96-0] (0.07 ml) and *N*-ethyl-*N*-(1-methylethyl)-2-propanamine [7087-68-5] (0.10 ml) were added. The reactor was closed and the mixture was heated for 7 days at 80°C. The reaction mixture was poured out into water and the product was extracted three times with dichloromethane. The combined organic layers were dried (MgSO₄), filtered and the solvent was evaporated, yielding fraction 1 of intermediate (14).

Two other fractions of Intermediate 14 were prepared as follows :

Intermediate (13) (0.00027 mol) and (3-aminopropyl)carbamic acid 1,1-dimethylethyl ester [75178-96-0] (0.00299 mol) were mixed in a (closed) reactor and heated at 100°C for 3 hours, yielding fraction 2 of intermediate (14).

30

-39-

Intermediate (13) (0.00008 mol) and (3-aminopropyl)carbamic acid 1,1-dimethylethyl ester [75178-96-0] (0.0009 mol) were mixed in an open reaction flask and heated at 80°C for 3 days, yielding fraction 3 of intermediate (14)

- 5 Fraction 1, 2 and 3 of intermediate 14 were combined and purified by flash column chromatography over silica gel.

Intermediate 14 was also prepared as follows :

- Intermediate (13) (0.00027 mol) was dissolved in DMF (3 ml). (3-
10 Aminopropyl)carbamic acid 1,1-dimethylethyl ester [75178-96-0] (0.00040 mol) and cesium carbonate (0.00135 mol) were added and the reaction mixture was stirred for 4 hours at 100°C, then overnight at 115°C. Excess of cesium carbonate was removed by filtration. The filtrate was evaporated, yielding intermediate (14).

d) Preparation of 4-{2-[6-(3-Amino-propylamino)-pyrido[3,4-d]pyrimidin-4-ylamino]-phenoxy}-butyric acid ethyl ester (intermediate 15)

- 15 Intermediate (14) (0.00055 mol) was dissolved in dichloromethane (11.00 ml). Trifluoroacetic acid (0.143 mol) was added and the reaction mixture was stirred for 2 hours at room temperature. The solvent and remaining acid were evaporated in the rotary evaporator. The resultant residue (oil) was dried (high-vacuum pump), yielding intermediate (15) (HPLC: 91% P; quantitative yield; used in next reaction step, without
20 further purification).

e) Preparation of 4-{2-[6-(3-Amino-propylamino)-pyrido[3,4-d]pyrimidin-4-ylamino]-phenoxy}-butyric acid (intermediate 16)

- Intermediate (15) (0.00055 mol) was dissolved in tetrahydrofuran (16.00 ml). Water (2.00 ml) was added. Lithium hydroxide.monohydrate (0.0055 mol) was added as a solid. More lithium hydroxide.monohydrate was added until a basic pH was reached
25 (until then it was acidic because of CF₃COOH remainders). The reaction mixture was stirred overnight at 65°C. The solvent was evaporated in the rotary evaporator, yielding intermediate (16) (HPLC: 88% P; quantitative yield; used in next reaction step, without further purification).

30 Example A7

a) Preparation of Allyl-(4-chloro-5-fluoro-2-nitro-benzyl)-methyl-amine (intermediate 17)

-40-

N-methyl-2-propen-1-amine (1.1 equiv) was added to a solution of 4-chloro-5-fluoro-2-nitro-benzaldehyde (1 equiv) in 1,2-dichloroethane (207 ml), then MgSO_4 (2 spoons) was added and the obtained solution was stirred for 2 hours at room temperature. $\text{NaBH}(\text{OAc})_3$ (3 equiv) was added in 5 portions (one portion per hour) and the reaction mixture was washed with K_2CO_3 . After extraction with CH_2Cl_2 , the layers were separated. The organic layer was dried over MgSO_4 , filtered and evaporated, to afford intermediate (17).

b) Preparation of 2-[(Allyl-methyl-amino)-methyl]-5-chloro-4-fluoro-phenylamine (intermediate 18)

A solution of the nitro derivative intermediate (17) (1 equiv) in a solution of H_2O (120 ml) and NH_4Cl (5 equiv) at room temperature was dissolved in Toluene (120 ml), then iron powder (5 equiv) was slowly added and the reaction mixture was stirred and refluxed at 105 °C. The obtained crude was purified by Flash Chromatography. The desired product fractions were collected and the solvent was evaporated, to afford 4.8 g of intermediate (18).

c) Preparation of {2-[(Allyl-methyl-amino)-methyl]-5-chloro-4-fluoro-phenyl}-(6-chloro-pyrido[3,2-*d*]pyrimidin-4-yl)-amine (intermediate 19)

Triethylamine (3 equiv) was added to a solution of 4,6-dichloro-pyrido[3,2-*d*]pyrimidine (1 equiv.) in acetonitrile (dried over Al_2CO_3) (9 ml). HCl evolved and the reaction mixture was purged with N_2 for 10 to 15 minutes. Intermediate (18) was added (1.7 equiv.) and then the reaction mixture was stirred and refluxed for 5 hours. After cooling to room temperature, a slightly yellow solid precipitated from the mixture. The product was collected and dried under high vacuum, to yield desired product. EtOAc was added to the mother layer and then a white solid precipitated. After filtration, the filtrate was concentrated and the obtained concentrate was purified by Flash chromatography over silica gel (eluent: Hexane/ EtOAc 9/1). The desired fractions were collected and the solvent was evaporated, to yield desired product. Both fractions of desired product were collected, to yield 0.750 g intermediate (19).

d) Preparation of N^6 -Allyl- N^4 -{2-[(allyl-methyl-amino)-methyl]-5-chloro-4-fluoro-phenyl}-pyrido[3,2-*d*]pyrimidine-4,6-diamine (intermediate 20)

A solution of intermediate (19) (1 equiv) in 2-propenylamine (9.8 equiv) was heated overnight in a sealed tube at 100 °C, then the resulting solution was concentrated and dried under high vacuum, to obtain 0.487 g (115 %) of a semi solid that was

-41-

redissolved in CH₂Cl₂. The solution was then filtered and the filtrate was concentrated again, to afford 0.412 g (100 %) of intermediate (20).

e) Preparation of 4,6-ethanediylidenepyrimido[4,5-

- 5 b][1,4,6,11]benzotetraazacyclotetradecine, 16-chloro-15-fluoro-7,8,11,12,13,18-hexahydro-12-methyl-, (9E)- (intermediate 21)

A mixture of intermediate (20) and Grubbs's Catalyst second generation (0.2 equiv) in CH₂Cl₂ (7 ml) was stirred and refluxed for 6 hours, then the reaction mixture was stirred for 72 hours at room temperature and refluxed again. An extra amount of B (20
10 %) was added and then the resulting mixture was stirred and refluxed again for 6 hours. Again extra B (20 %) was added and the mixture was refluxed again overnight. After concentration, the obtained residue was purified by Flash chromatography over silica gel (eluent: Acetate/Hexane 1/1). The desired fraction were collected and the solvent was evaporated, to yield 0.025 g (38 %) of pure intermediate (21).

15

B. Preparation of the compounds

Example B1

Preparation of 7*H*,19*H*-4,6-ethanediylidenepyrimido[4,5-*b*][13,1,4,6]benzoxatriazacyclopentadecine, 17-chloro-8,9,10,11,12,13-hexahydro- (compound 1)

- In two separate dropping funnels, a solution of tributylphosphine (0.00268 mol) in THF (20 ml) and a solution of ADDP (0.00155 mol) in THF (20 ml) were slowly
20 simultaneously added to a solution of intermediate 2 (0.00103 mol) in THF (20 ml) and DMF (2 ml) chilled at 0°C under an atmosphere of nitrogen. The reaction mixture was stirred for 4 hours at room temperature, poured out into a 1N solution of aqueous hydrochloric acid and after 1 hour, the mixture was diluted with DCM. The precipitate was filtered off, the organic phase was partitioned with a 10% aqueous solution of
25 potassium carbonate, dried (MgSO₄) and concentrated in vacuo. The solid residue was sonicated in hot isopropanol, filtered off, washed with dry ether and dried in vacuo, yielding 0.16g (44%) of compound (1).

Example B2

Preparation of 6,4-(nitrilometheno)pyrimido[4,5-*b*][13,1,4,6]benzoxatriazacyclopentadecine, 17-chloro-7,8,9,10,11,12,13,19-octahydro- (compound 2)

- 30 In two separate dropping funnels, a solution of ADDP (0.00102 mol) in THF (2 ml) and a solution of tributylphosphine (0.00177 mol) in THF (2 ml) were slowly

-42-

- simultaneously added to a solution of intermediate 6 (0.000681 mol) in THF (10 ml) and DMF (1.4 ml), and stirred at room temperature for 18 hours. Then, a solution of ADDP (0.000340 mol) in THF (0.7 mL) and a solution of tributylphosphine (0.000592 mol) in THF (0.7 mL) were simultaneously added at room temperature for 2 hours. The
- 5 mixture was hydrolyzed and the precipitate was filtered off, wash with water then with isopropanol and the diethyl ether, and dried in vacuo, yielding 0.124g (49%) of compound (2), melting point >260°C.

Example B3

- Preparation of 7*H*,21*H*-4,6-ethanediylidenepyrimido[4,5-*b*][15,1,4,6,10]benzoxa-tetraazacycloheptadecin-12(13*H*)-one, 8,9,10,11,14,15-hexahydro- (compound 3)
- 10 1-[bis(dimethylamino)methylene]-3-oxide-1*H*-benzotriazolium, hexafluorophosphate(1-) [94790-37-1] (0.00057 mol) was dissolved in DMF (20 ml) and stirred at room temperature. Intermediate (11) (0.00019 mol) was dissolved in DMF (10 ml) and *N*-ethyl-*N*-(1-methylethyl)- 2-propanamine (0.00114 mol) was added. This solution
- 15 was added slowly over a 2 hours period to the first solution. The light-green solution was stirred overnight at room temperature. The solvent (DMF) was evaporated. The residue was purified by flash column chromatography, yielding compound (3).

Compounds that are prepared according to Example B3	
4,6-ethanediylidenepyrimido[4,5- <i>b</i>][1,4,6,10,13]benzopentaazacyclohexadecin-12(7 <i>H</i>)-one, 18-chloro-17-fluoro-8,9,10,11,13,14,15,20-octahydro-	Compound 6
-4,6-ethanediylidenepyrimido[4,5- <i>b</i>]pyrrolo[2,1- <i>l</i>][1,4,6,10,13]benzopentaazacyclohexadecin-12(7 <i>H</i>)-one, 20-chloro-19-fluoro-8,9,10,11,12a,13,14,15,17,22-decahydro-	Compound 7
-4,6-ethanediylidenepyrimido[4,5- <i>b</i>][1,4,6,10,13]benzopentaazacyclohexadecin-12(7 <i>H</i>)-one, 18-chloro-17-fluoro-8,9,10,11,13,14,15,20-octahydro-14-methyl-	Compound 8
4,6-ethanediylidene-11 <i>H</i> -pyrimido[4,5- <i>b</i>][1,4,6,9,12]benzopentaazacyclopentadecin-11-one, 17-chloro-16-fluoro-7,8,9,10,12,13,14,19-octahydro-13-methyl-	Compound 9
4,6-ethanediylidenepyrimido[4,5- <i>b</i>][1,4,6,10,13]benzopentaazacyclohexadecin-12(7 <i>H</i>)-one, 18-chloro-17-fluoro-8,9,10,11,13,14,15,20-octahydro-13-(2-	Compound 10

-43-

4,6-ethanediylidenepyrimido[4,5-b][1,4,6,10,13]benzopentaazacyclooctadecin-15(16H)-one, 20-bromo-7,8,9,10,11,12,13,14,17,22-decahydro-	Compound 11
4,6-ethanediylidenepyrimido[4,5-b][1,4,6,10,14]benzopentaazacyclooctadecin-16(7H)-one, 20-chloro-8,9,10,11,12,13,14,15,17,22-decahydro-	Compound 12
4,6-ethanediylidene-7H-pyrimido[4,5-b][1,4,6,10,14]benzopentaazacyclononadecin-16(17H)-one, 21-chloro-8,9,10,11,12,13,14,15,18,23-decahydro-	Compound 13
4,6-ethanediylidenepyrimido[4,5-b][1,4,6,10,13]benzopentaazacyclooctadecin-15(16H)-one, 20-chloro-7,8,9,10,11,12,13,14,17,22-decahydro-	Compound 14

Example B4

Preparation of 7*H*,21*H*-6,4-(nitrilometheno)pyrimido[5,4-*m*][1,6,10,15]benzoxatriazacycloheptadecin-12(13*H*)-one, 8,9,10,11,14,15-hexahydro- (compound 4)

- 1-[bis(dimethylamino)methylene]-3-oxide-1*H*-benzotriazolium, hexafluorophosphate(1-) [94790-37-1] (0.00165 mol) was dissolved in DMF (40 ml) and stirred at room temperature. Intermediate (16) (0.00055 mol) was dissolved in DMF (20 ml) and *N*-ethyl-*N*-(1-methylethyl)-2-propanamine (0.0033 mol) was added. This solution was added slowly over a 2 hours period to the first solution. The light-green solution was stirred overnight at room temperature. The solvent (DMF) was evaporated, yielding compound (4).

10

Compounds that are prepared according to Example B4	
6,4-(nitrilometheno)pyrimido[4,5-b][1,6,10,13]benzotetraazacyclohexadecin-12(7H)-one, 18-chloro-17-fluoro-8,9,10,11,13,14,15,20-octahydro-	Compound 15
-6,4-(nitrilometheno)pyrimido[4,5-b]pyrrolo[2,1- <i>l</i>][1,6,10,13]benzotetraazacyclohexadecin-12(7H)-one, 20-chloro-19-fluoro-8,9,10,11,12a,13,14,15,17,22-decahydro-	Compound 16
-6,4-(nitrilometheno)pyrimido[4,5-b][1,6,10,13]benzotetraazacyclohexadecin-12(7H)-one, 18-chloro-17-fluoro-8,9,10,11,13,14,15,20-octahydro-14-methyl-	Compound 17

6,4-(nitrilometheno)-11H-pyrimido[4,5-b][1,6,9,12]benzotetraazacyclopentadecin-11-one, 17-chloro-16-fluoro-7,8,9,10,12,13,14,19-octahydro-13-methyl-	Compound 18
6,4-(nitrilometheno)pyrimido[4,5-b][1,6,10,13]benzotetraazacyclohexadecin-12(7H)-one, 18-chloro-17-fluoro-8,9,10,11,13,14,15,20-octahydro-13-(2-methylpropyl)-	Compound 19
6,4-(nitrilometheno)pyrimido[4,5-b][1,6,10,13]benzotetraazacyclooctadecin-15(16H)-one, 20-bromo-7,8,9,10,11,12,13,14,17,22-decahydro-	Compound 20
6,4-(nitrilometheno)pyrimido[4,5-b][1,6,10,14]benzotetraazacyclooctadecin-16(7H)-one, 20-chloro-8,9,10,11,12,13,14,15,17,22-decahydro-	Compound 21
6,4-(nitrilometheno)-7H-pyrimido[4,5-b][1,6,10,14]benzotetraazacyclononadecin-16(17H)-one, 21-chloro-8,9,10,11,12,13,14,15,18,23-decahydro-	Compound 22
6,4-(nitrilometheno)pyrimido[4,5-b][1,6,10,13]benzotetraazacyclooctadecin-15(16H)-one, 20-chloro-7,8,9,10,11,12,13,14,17,22-decahydro-	Compound 23

All other compounds can be prepared according to these procedures with the remark that the cpds with Y being C₁₋₅ alkyl and X²/X¹ NH are cyclized under ring closing metathesis conditions using second generation Grubbs catalysts of the dienes (see example B5 hereinafter)

Example B5

Preparation of 4,6-ethanediylidenepyrimido[4,5-b][1,4,6,11]benzotetraazacyclotetradecine, 16-chloro-15-fluoro-7,8,9,10,11,12,13,18-octahydro-12-methyl- (compound 5)

Intermediate (21) (1 equiv) was dissolved in a methanol/dioxane mixture (4/1), then catalyst Pt/C (0.3 equiv) was added and the reaction mixture was stirred for 4 hours under H₂ atmosphere. The resulting mixture was filtered over a short celite pad and the filtrate was concentrated to dryness. The obtained residue was dried under high vacuum, to afford 0.029 g (60 %) of pure compound (5).

Compound identification

The compounds were identified by LC/MS using a gradient elution system on a reversed phase HPLC. The compounds are identified by their specific retention time and their protonated molecular ion MH^+ peak. The HPLC gradient was supplied by a Waters Alliance HT 2790 system with a column heater set at 40°C. Flow from the column was split to a Waters 996 photodiode array (PDA) detector and a Waters-Micromass ZQ mass spectrometer with an electrospray ionization source operated in positive and negative ionization mode. Reversed phase HPLC was carried out on a Xterra MS C18 column (3.5 μm , 4.6 x 100 mm) with a flow rate of 1.6 ml/min. Three mobile phases (mobile phase A 95% 25mM ammoniumacetate + 5% acetonitrile; mobile phase B: acetonitrile; mobile phase C: methanol) were employed to run a gradient condition from 100 % A to 50% B and 50% C in 6.5 minutes, to 100 % B in 1 minute, 100% B for 1 minute and reequilibrate with 100 % A for 1.5 minutes. An injection volume of 10 μL was used. Mass spectra were acquired by scanning from 100 to 1000 in 1 s using a dwell time of 0.1 s. The capillary needle voltage was 3kV and the source temperature was maintained at 140°C. Nitrogen was used as the nebulizer gas. Cone voltage was 10 V for positive ionization mode and 20 V for negative ionization mode. Data acquisition was performed with a Waters-Micromass MassLynx-Openlynx data system.

Table : retention time (RT in minutes) and molecular weight as the MH^+

Compound No.	Rt	MH^+
9	6.57	416
5	8.78	387
7	6.87	456
11	5.44	470
14	5.42	426
Int.20	8.62	413
Int.21	8.06	387
3	6.08	379
4	5.77	379

C. Pharmacological examples

Example C.1 : in vitro inhibition of EGFR

The *in vitro* inhibition of EGFR was assessed using either the Flash Plate technology or the glass-fiber filter technology as described by Davies, S.P. et al., Biochem J. (2000), 351; p.95-105. The Flash Plate technology is generally described by B.A. Brown *et al.*

-46-

in High Throughput Screening (1997), p.317-328. Editor(s): Devlin, John P.
Publisher: Dekker, New York, N. Y.

In the Flash Plate EGFR kinase reaction assay, a kinase substrate consisting of
5 biotinylated poly(L-glutamic acid-L-tyrosine) (poly(GT)biotin), is incubated with the
aforementioned protein in the presence of (^{33}P) radiolabeled ATP. (^{33}P) phosphorylation
of the substrate is subsequently measured as light energy emitted using a streptavidin-
coated Flash Plate (PerkinElmer Life Sciences) by trapping and quantifying the binding
of the biotin tagged and radiolabeled substrate.

10

Detailed description

The EGFR kinase reaction is performed at 30°C for 60 minutes in a 96-well microtiter
FlashPlate (PerkinElmer Life Sciences). For each of the tested compounds a full dose
response 1.10^{-6}M to 1.10^{-10}M has been performed. IRESSA® and Tarceva™ (erlotinib)
15 were used as reference compounds. The 100 μl reaction volume contains 54.5 mM
TrisHCl pH 8.0, 10 mM MgCl_2 , 100 μM Na_3VO_4 , 5.0 μM unlabeled ATP, 1mM DTT,
0.009% BSA, 0.8 μCi AT^{33}P , 0.35 $\mu\text{g/well}$ poly(GT)biotin and 0.5 μg EGFR-kinase
domain/well.

20

The reaction is stopped by aspirating the reaction mixture and washing the plate 3x
with 200 μl wash/stop buffer (PBS + 100 mM EDTA). After the final wash step 200 μl
of wash/stop buffer was added to each well and the amount of phosphorylated (^{33}P)
Poly(GT)biotin determined by counting (30-sec/well) in a microtiterplate scintillation
counter.

25

In the glass-fiber filter technology EGFR kinase reaction assay, a kinase substrate
consisting of poly(L-glutamic acid-L-tyrosine) (poly(GT)), is incubated with the
aforementioned protein in the presence of (^{33}P) radiolabeled ATP. (^{33}P) Phosphorylation
of the substrate is subsequently measured as radioactivity bound on a glassfiber-filter.

-47-

Detailed description

The EGFR kinase reaction is performed at 25°C for 10 minutes in a 96-well microtiterplate. For each of the tested compounds a full dose response 1.10⁻⁶M to 1.10⁻¹⁰M has been performed. IRESSA® and Tarceva™ (erlotinib) were used as reference compounds. The 25 µl reaction volume contains 60 mM TrisHCl pH 7.5, 3 mM MgCl₂, 3 mM Mn Cl₂, 3 µM Na₃VO₄, 50 µg/ml PEG20000, 5.0 µM unlabeled ATP, 1mM DTT, 0.1 µCi AT³³P, 62.5 ng/well poly(GT) and 0.5 µg EGFR-kinase domain/well.

The reaction is stopped by adding 5 µl of a 3% phosphoric acid solution. 10 µl of the reaction mixture is then spotted onto a Filtermat A filter (Wallac) and washed 3 times for 5 min. in 75 mM phosphoric acid and 1 time for 5 min. in methanol prior to drying and quantification on the Typhoon (Amersham) using a LE phosphorage storage screen.

15 Example C.2: Serum starved proliferation assay on the ovarian carcinoma SKOV3 cells

The ovarian carcinoma cell line (SKOV3) was used in an epidermal growth factor stimulated cell proliferation assay, to assess the inhibitory effect of the compounds on EGF in whole cells.

20 In a first step the SKOV3 cells were incubated for 24 hours in the presence of 10% FCS serum. In the second step the cells were incubated with the compounds to be tested in a serum free condition (37 °C and 5% (v/v) CO₂) and subsequently stimulated for 72 hours with EGF at a final concentration of 100 ng/ml. The effect of the compounds on the EGF stimulation was finally assessed in a standard MTT cell viability assay.

25

The following table provides the pIC50 values of the compounds according to the invention, obtained using the above mentioned kinase assays.

Compound number	<i>In vitro</i> kinase activity assay.(C1) : IC50 in nM	SKOV3 cell (C2) : IC50 in µM
2	8.5	< 5.0

Intermediate number	<i>In vitro</i> kinase activity assay.(C1) : IC50 in nM	SKOV3 cell (C2) : IC50 in µM
2	8.2	5.5
3	8.4	6.1

-48-

Compound number	<i>In vitro</i> kinase activity assay (C1) : IC50 in nM	SKOV3 cell (C2) : IC50 in μ M
1	8.3	6.23

Intermediate number	<i>In vitro</i> kinase activity assay (C1) : IC50 in nM	SKOV3 cell (C2) : IC50 in μ M
4	8.3	5.8
6	8.4	6.0

D. Composition examples

The following formulations exemplify typical pharmaceutical compositions suitable for systemic administration to animal and human subjects in accordance with the present invention.

- 5 "Active ingredient" (A.I.) as used throughout these examples relates to a compound of formula (I), (XXXI) or a pharmaceutically acceptable addition salt thereof.

Example D.1 : film-coated tablets

Preparation of tablet core


- 10 A mixture of A.I. (100 g), lactose (570 g) and starch (200 g) was mixed well and thereafter humidified with a solution of sodium dodecyl sulfate (5 g) and polyvinyl-pyrrolidone (10 g) in about 200 ml of water. The wet powder mixture was sieved, dried and sieved again. Then there was added microcrystalline cellulose (100 g) and hydrogenated vegetable oil (15 g). The whole was mixed well and compressed into tablets, giving 10.000 tablets, each comprising 10 mg of the active ingredient.

Coating

- 15 To a solution of methyl cellulose (10 g) in denaturated ethanol (75 ml) there was added a solution of ethyl cellulose (5 g) in CH_2Cl_2 (150 ml). Then there were added CH_2Cl_2 (75 ml) and 1,2,3-propanetriol (2.5 ml). Polyethylene glycol (10 g) was molten and dissolved in dichloromethane (75 ml). The latter solution was added to the former and then there were
20 added magnesium octadecanoate (2.5 g), polyvinyl-pyrrolidone (5 g) and concentrated color suspension (30 ml) and the whole was homogenated. The tablet cores were coated with the thus obtained mixture in a coating apparatus.

Claims

1. A compound having the formula



- 5 the *N*-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein

$a^1-a^2=a^3-a^4$ represents a divalent radical selected from N-CH=CH-CH₂, N-CH=N-CH or CH-CH=N-CH₂;

- 10 Z represents O, NH or S;

Y represents -C₃₋₉alkyl-, -C₃₋₉alkenyl-, -C₁₋₅alkyl-oxy-C₁₋₅alkyl-,

-C₁₋₅alkyl-NR¹³-C₁₋₅alkyl-, -C₁₋₅alkyl-NR¹⁴-CO-C₁₋₅alkyl-,

-C₁₋₅alkyl-CO-NR¹⁵-C₁₋₅alkyl-, -C₁₋₆alkyl-CO-NH-,

-C₁₋₆alkyl-NH-CO-, -CO-NH-C₁₋₆alkyl-, -NH-CO-C₁₋₆alkyl-, -CO-C₁₋₇alkyl-,

- 15 -C₁₋₇alkyl-CO-, C₁₋₆alkyl-CO-C₁₋₆alkyl;

X¹ represents a direct bond, O, -O-C₁₋₂alkyl-, CO, -CO-C₁₋₂alkyl-, NR¹¹,

-NR¹¹-C₁₋₂alkyl-, NR¹⁶-CO-, NR¹⁶-CO-C₁₋₂alkyl-, -O-N=CH- or C₁₋₂alkyl;

X² represents a direct bond, O, -O-C₁₋₂alkyl-, CO, -CO-C₁₋₂alkyl-, NR¹²,

NR¹²-C₁₋₂alkyl-, NR¹⁷-CO-, NR¹⁷-CO-C₁₋₂alkyl-, Het²⁰-C₁₋₂alkyl-, -O-N=CH- or

- 20 C₁₋₂alkyl;

R¹ represents hydrogen, cyano, halo, hydroxy, formyl, C₁₋₆alkoxy-, C₁₋₆alkyl-,

C₁₋₆alkoxy- substituted with halo,

C₁₋₄alkyl substituted with one or where possible two or more substituents selected from hydroxy or halo;

- 25 R² represents hydrogen, cyano, halo, hydroxy, hydroxycarbonyl-, Het¹⁶-carbonyl-,

C₁₋₄alkyloxycarbonyl-, C₁₋₄alkylcarbonyl-, aminocarbonyl-, mono-or

di(C₁₋₄alkyl)aminocarbonyl-, Het¹, formyl, C₁₋₄alkyl-, C₂₋₆alkynyl-, C₃₋₆cycloalkyl-,

C₃₋₆cycloalkyloxy-, C₁₋₆alkoxy-, Ar⁵, Ar¹-oxy-, dihydroxyborane,

C₁₋₆alkoxy- substituted with halo,


-50-

- C₁₋₄alkyl substituted with one or where possible two or more substituents selected from halo, hydroxy or NR⁵R⁶,
 C₁₋₄alkylcarbonyl- wherein said C₁₋₄alkyl is optionally substituted with one or where possible two or more substituents selected from hydroxy or
 5 C₁₋₄alkyl-oxy-;
 R³ represents hydrogen, C₁₋₄alkyl, cyano or C₁₋₄alkyl substituted with one or more substituents selected from halo, C₁₋₄alkyloxy-, amino-, mono- or di(C₁₋₄alkyl)amino-, C₁₋₄alkyl-sulfonyl- or phenyl;
 R⁴ represents hydrogen, hydroxy, Ar³-oxy, Ar⁴-C₁₋₄alkyloxy-, C₁₋₄alkyloxy-,
 10 C₂₋₄alkenyloxy- optionally substituted with Het¹² or R⁴ represents C₁₋₄alkyloxy substituted with one or where possible two or more substituents selected from C₁₋₄alkyloxy-, hydroxy, halo, Het²-, -NR⁷R⁸, -carbonyl- NR⁹R¹⁰ or Het³-carbonyl-;
 R⁵ and R⁶ are each independently selected from hydrogen or C₁₋₄alkyl;
 R⁷ and R⁸ are each independently selected from hydrogen, C₁₋₄alkyl, Het⁸,
 15 aminosulfonyl-, mono- or di (C₁₋₄alkyl)-aminosulfonyl, hydroxy-C₁₋₄alkyl-, C₁₋₄alkyl-oxy-C₁₋₄alkyl-, hydroxycarbonyl-C₁₋₄alkyl-, C₃₋₆cycloalkyl, Het⁹-carbonyl-C₁₋₄alkyl-, Het¹⁰-carbonyl-, polyhydroxy-C₁₋₄alkyl-, Het¹¹-C₁₋₄alkyl- or Ar²-C₁₋₄alkyl-;
 R⁹ and R¹⁰ are each independently selected from hydrogen, C₁₋₄alkyl, C₃₋₆cycloalkyl, Het⁴, hydroxy-C₁₋₄alkyl-, C₁₋₄alkyloxyC₁₋₄alkyl- or polyhydroxy-C₁₋₄alkyl-;
 20 R¹¹ represents hydrogen, C₁₋₄alkyl, Het⁵, Het⁶-C₁₋₄alkyl-, C₂₋₄alkenylcarbonyl- optionally substituted with Het⁷-C₁₋₄alkylaminocarbonyl-, C₂₋₄alkenylsulfonyl-, C₁₋₄alkyloxyC₁₋₄alkyl- or phenyl optionally substituted with one or where possible two or more substituents selected from hydrogen, hydroxy, amino or C₁₋₄alkyloxy-;
 25 R¹² represents hydrogen, C₁₋₄alkyl, C₁₋₄alkyl-oxy-carbonyl-, Het¹⁷, Het¹⁸-C₁₋₄alkyl-, C₂₋₄alkenylcarbonyl- optionally substituted with Het¹⁹-C₁₋₄alkylaminocarbonyl-, C₂₋₄alkenylsulfonyl-, C₁₋₄alkyloxyC₁₋₄alkyl- or phenyl optionally substituted with one or where possible two or more substituents selected from hydrogen, hydroxy, amino or C₁₋₄alkyloxy-;
 30 R¹³ represents hydrogen, C₁₋₄alkyl, Het¹³, Het¹⁴-C₁₋₄alkyl- or phenyl optionally substituted with one or where possible two or more substituents selected from hydrogen, hydroxy, amino or C₁₋₄alkyloxy-;
 R¹⁴ and R¹⁵ are each independently selected from hydrogen, C₁₋₄alkyl, Het¹⁵-C₁₋₄alkyl- or C₁₋₄alkyloxyC₁₋₄alkyl-;
 35 R¹⁶ and R¹⁷ are each independently selected from hydrogen, C₁₋₄alkyl, Het²¹-C₁₋₄alkyl- or C₁₋₄alkyloxyC₁₋₄alkyl-;

-51-

- Het¹ represents a heterocycle selected from piperidinyl, morpholinyl, piperazinyl, furanyl, pyrazolyl, dioxolanyl, thiazolyl, oxazolyl, imidazolyl, isoxazolyl, oxadiazolyl, pyridinyl or pyrrolidinyl wherein said Het¹ is optionally substituted with one or where possible two or more substituents selected from amino, C₁₋₄alkyl, hydroxy-C₁₋₄alkyl-, phenyl, phenyl-C₁₋₄alkyl-, C₁₋₄alkyl-oxy-C₁₋₄alkyl- mono- or di(C₁₋₄alkyl)amino- or amino-carbonyl-;
- Het² represents a heterocycle selected from morpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, thiomorpholinyl or dithianyl wherein said Het² is optionally substituted with one or where possible two or more substituents selected from hydroxy, halo, amino, C₁₋₄alkyl-, hydroxy-C₁₋₄alkyl-, C₁₋₄alkyl-oxy-C₁₋₄alkyl-, hydroxy-C₁₋₄alkyl-oxy-C₁₋₄alkyl-, mono- or di(C₁₋₄alkyl)amino-, mono- or di(C₁₋₄alkyl)amino-C₁₋₄alkyl-, aminoC₁₋₄alkyl-, mono- or di(C₁₋₄alkyl)amino-sulfonyl-, aminosulfonyl-;
- Het³, Het⁴ and Het⁸ each independently represent a heterocycle selected from morpholinyl, piperazinyl, piperidinyl, furanyl, pyrazolyl, dioxolanyl, thiazolyl, oxazolyl, imidazolyl, isoxazolyl, oxadiazolyl, pyridinyl or pyrrolidinyl wherein said Het³, Het⁴ or Het⁸ is optionally substituted with one or where possible two or more substituents selected from hydroxy-, amino-, C₁₋₄alkyl-, C₃₋₆cycloalkyl-C₁₋₄alkyl-, aminosulfonyl-, mono- or di(C₁₋₄alkyl)aminosulfonyl or amino-C₁₋₄alkyl-;
- Het⁵ represent a heterocycle selected from pyrrolidinyl or piperidinyl wherein said heterocycle is optionally substituted with one or where possible two or more substituents selected from C₁₋₄alkyl, C₃₋₆cycloalkyl, hydroxy-C₁₋₄alkyl-, C₁₋₄alkyloxyC₁₋₄alkyl or polyhydroxy-C₁₋₄alkyl-;
- Het⁶ and Het⁷ each independently represent a heterocycle selected from morpholinyl, pyrrolidinyl, piperazinyl or piperidinyl wherein said Het⁶ and Het⁷ are optionally substituted with one or where possible two or more substituents selected from C₁₋₄alkyl, C₃₋₆cycloalkyl, hydroxy-C₁₋₄alkyl-, C₁₋₄alkyloxyC₁₋₄alkyl or polyhydroxy-C₁₋₄alkyl-;
- Het⁹ and Het¹⁰ each independently represent a heterocycle selected from furanyl, piperidinyl, morpholinyl, piperazinyl, pyrazolyl, dioxolanyl, thiazolyl, oxazolyl, imidazolyl, isoxazolyl, oxadiazolyl, pyridinyl or pyrrolidinyl wherein said Het⁹ or Het¹⁰ is optionally substituted C₁₋₄alkyl, C₃₋₆cycloalkyl-C₁₋₄alkyl- or amino-C₁₋₄alkyl-;

- 35 Het¹¹ represents a heterocycle selected from indolyl or



- Het¹² represents a heterocycle selected from morpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, thiomorpholinyl or dithianyl wherein said Het¹² is optionally substituted with one or where possible two or more substituents selected from hydroxy, halo, amino, C₁₋₄alkyl-, hydroxy-C₁₋₄alkyl-, C₁₋₄alkyl-oxy-C₁₋₄alkyl-, hydroxy-C₁₋₄alkyl-oxy-C₁₋₄alkyl-, mono- or di(C₁₋₄alkyl)amino- or mono- or di(C₁₋₄alkyl)amino-C₁₋₄alkyl-;
- Het¹³ represent a heterocycle selected from pyrrolidinyl or piperidinyl wherein said heterocycle is optionally substituted with one or where possible two or more substituents selected from C₁₋₄alkyl, C₃₋₆cycloalkyl, hydroxy-C₁₋₄alkyl-, C₁₋₄alkyloxyC₁₋₄alkyl or polyhydroxy-C₁₋₄alkyl-;
- Het¹⁴ represent a heterocycle selected from morpholinyl, pyrrolidinyl, piperazinyl or piperidinyl wherein said heterocycle is optionally substituted with one or where possible two or more substituents selected from C₁₋₄alkyl, C₃₋₆cycloalkyl, hydroxy-C₁₋₄alkyl-, C₁₋₄alkyloxyC₁₋₄alkyl or polyhydroxy-C₁₋₄alkyl-;
- Het¹⁵ and Het²¹ each independently represent a heterocycle selected from morpholinyl, pyrrolidinyl, piperazinyl or piperidinyl wherein said Het¹⁵ or Het²¹ are optionally substituted with one or where possible two or more substituents selected from C₁₋₄alkyl, C₃₋₆cycloalkyl, hydroxy-C₁₋₄alkyl-, C₁₋₄alkyloxyC₁₋₄alkyl or polyhydroxy-C₁₋₄alkyl-;
- Het¹⁶ represent a heterocycle selected from morpholinyl, pyrrolidinyl, piperazinyl, 1,3,2-dioxaborolane or piperidinyl wherein said heterocycle is optionally substituted with one or more substituents selected from C₁₋₄alkyl-;
- Het¹⁷ represent a heterocycle selected from pyrrolidinyl or piperidinyl wherein said heterocycle is optionally substituted with one or where possible two or more substituents selected from C₁₋₄alkyl, C₃₋₆cycloalkyl, hydroxy-C₁₋₄alkyl-, C₁₋₄alkyloxyC₁₋₄alkyl or polyhydroxy-C₁₋₄alkyl-;
- Het¹⁸ and Het¹⁹ each independently represent a heterocycle selected from morpholinyl, pyrrolidinyl, piperazinyl or piperidinyl wherein said Het¹⁸ and Het¹⁹ are optionally substituted with one or where possible two or more substituents selected from C₁₋₄alkyl, C₃₋₆cycloalkyl, hydroxy-C₁₋₄alkyl-, C₁₋₄alkyloxyC₁₋₄alkyl or polyhydroxy-C₁₋₄alkyl-;
- Het²⁰ represents a heterocycle selected from pyrrolidinyl, 2-pyrrolidinyl, piperidinyl, piperazinyl or pyrazolidinyl wherein said heterocycle is optionally substituted with one or where possible two or more substituents selected from C₁₋₄alkyl, C₃₋₆cycloalkyl, hydroxy-C₁₋₄alkyl-, C₁₋₄alkyloxyC₁₋₄alkyl or polyhydroxy-C₁₋₄alkyl-; and

-53-

Ar¹, Ar², Ar³, Ar⁴ and Ar⁵ each independently represent phenyl optionally substituted with cyano, C₁₋₄alkylsulfonyl-, C₁₋₄alkylsulfonylamino-, aminosulfonylamino-, hydroxy-C₁₋₄alkyl, aminosulfonyl-, hydroxy-, C₁₋₄alkyloxy- or C₁₋₄alkyl.

5 2. A compound according to claim 1 wherein;

Z represents NH;

Y represents -C₃₋₉alkyl-, -C₂₋₉alkenyl-, -C₁₋₅alkyl-oxy-C₁₋₅alkyl-,
-C₁₋₅alkyl-NR¹³-C₁₋₅alkyl-, -C₁₋₅alkyl-NR¹⁴-CO-C₁₋₅alkyl-, -C₁₋₆alkyl-NH-CO-, -
CO-C₁₋₇alkyl-, -C₁₋₇alkyl-CO- or C₁₋₆alkyl-CO-C₁₋₆alkyl;

10 X¹ represents O, -O-C₁₋₂alkyl-, -O-N=CH-, NR¹¹ or -NR¹¹-C₁₋₂alkyl-; in a particular embodiment X¹ represents a direct bond, C₁₋₂alkyl-, -O-C₁₋₂alkyl-, NR¹¹-, -O- or -O-CH₂-;

X² represents a direct bond, O, -O-C₁₋₂alkyl-, -O-N=CH-, NR¹⁷-CO-,
NR¹⁷-CO-C₁₋₂alkyl-, C₁₋₂alkyl, Het²⁰-C₁₋₂alkyl-, NR¹² or NR¹²-C₁₋₂alkyl-; in a
15 particular embodiment X² represents a direct bond, C₁₋₂alkyl-, -O-C₁₋₂alkyl,
NR¹⁷-CO-, NR¹⁷-CO-C₁₋₂alkyl-, Het²⁰-C₁₋₂alkyl-, -O- or -O-CH₂-;

R¹ represents hydrogen, cyano, halo or hydroxy, preferably halo;

R² represents hydrogen, cyano, halo, hydroxy, hydroxycarbonyl-,
C₁₋₄alkyloxycarbonyl-, Het¹⁶-carbonyl-, C₁₋₄alkyl-, C₂₋₆alkynyl-, Ar⁵ or Het¹;
20 in a further embodiment R² represents hydrogen, cyano, halo, hydroxy,
or Ar⁵; in a more particular embodiment R² represents hydrogen or halo;

R³ represents hydrogen;

R⁴ represents hydrogen, hydroxy, C₁₋₄alkyloxy-, Ar⁴-C₁₋₄alkyloxy or R⁴ represents
C₁₋₄alkyloxy substituted with one or where possible two or more substituents
25 selected from
C₁₋₄alkyloxy- or Het²-;

R¹¹ represents hydrogen, C₁₋₄alkyl- or C₁₋₄alkyl-oxy-carbonyl-;

R¹² represents hydrogen, C₁₋₄alkyl- or C₁₋₄alkyl-oxy-carbonyl-;

R¹³ represents hydrogen or Het¹⁴-C₁₋₄alkyl, in particular morpholinyl-C₁₋₄alkyl;

30 R¹⁴ represents hydrogen or C₁₋₄alkyl;

R¹⁷ represents hydrogen, C₁₋₄alkyl-, Het²¹-C₁₋₄alkyl or C₁₋₄alkyl-oxy-C₁₋₄alkyl; in
particular R¹⁷ represents hydrogen or C₁₋₄alkyl;

Het¹ represents thiazolyl optionally substituted with amino, C₁₋₄alkyl, hydroxy-C₁₋₄
alkyl-, phenyl, phenyl-C₁₋₄alkyl-, C₁₋₄alkyl-oxy-C₁₋₄alkyl-, mono- or di(C₁₋₄
35 alkyl)amino- or amino-carbonyl-;

-54-

- Het² represents a heterocycle selected from morpholinyl, piperazinyl, piperidinyl or pyrrolidinyl wherein said Het² is optionally substituted with one or where possible two or more substituents selected from hydroxy, amino or C₁₋₄alkyl-;
- In a further embodiment Het² represents a heterocycle selected from morpholinyl or piperidinyl optionally substituted with C₁₋₄alkyl-, preferably methyl;
- Het¹⁴ represents a heterocycle selected from morpholinyl, piperazinyl, piperidinyl or pyrrolidinyl wherein said Het¹⁴ is optionally substituted with one or where possible two or more substituents selected from hydroxy, amino or C₁₋₄alkyl-;
- Het¹⁶ represents a heterocycle selected from piperidinyl, morpholinyl or pyrrolidinyl;
- Het²⁰ represents a heterocycle selected from pyrrolidinyl, 2-pyrrolidinyl or piperidinyl;
- Het²¹ represents a heterocycle selected from morpholinyl, piperazinyl, piperidinyl or pyrrolidinyl wherein said Het²¹ is optionally substituted with one or where possible two or more substituents selected from hydroxy, amino or C₁₋₄alkyl-;
- Ar⁴ represents phenyl optionally substituted with cyano, hydroxy-, C₁₋₄alkyloxy or C₁₋₄alkyl-;
- Ar⁵ represents phenyl optionally substituted with cyano, hydroxy, C₁₋₄alkyloxy or C₁₋₄alkyl.
3. A compound according to claim 1 wherein;
- Z represents NH;
- Y represents -C₃₋₉alkyl-, -C₁₋₅alkyl-NR¹³-C₁₋₅alkyl-, -C₁₋₅alkyl-NR¹⁴-CO-C₁₋₅alkyl-, -C₁₋₆alkyl-NH-CO- or -CO-NH-C₁₋₆alkyl- ;
- X¹ represents -O-, -NR¹¹-, -NR¹⁶-CO-, or -NR¹⁶-CO-C₁₋₂alkyl-;
- X² represents a direct bond, -C₁₋₂alkyl-, -O-C₁₋₂alkyl-, -O-, -O-CH₂- or Het²⁰-C₁₋₂alkyl-;
- R¹ represents hydrogen or halo;
- R² represents hydrogen, cyano, halo, hydroxycarbonyl-, C₁₋₄alkyloxycarbonyl-, Het¹⁶-carbonyl- or Ar⁵; in particular R² represents hydrogen or halo;
- R³ represents hydrogen;
- R⁴ represents hydrogen, hydroxy, C₁₋₄alkyloxy-, Ar⁴-C₁₋₄alkyloxy or R⁴ represents C₁₋₄alkyloxy substituted with one or where possible two or more substituents selected from C₁₋₄alkyloxy- or Het²-;
- R¹¹ represents hydrogen;
- R¹² represents hydrogen, C₁₋₄alkyl- or C₁₋₄alkyl-oxy-carbonyl-;
- R¹³ represents hydrogen or Het¹⁴-C₁₋₄alkyl, in particular hydrogen or morpholinyl-C₁₋₄alkyl;

-55-

Het² represents a heterocycle selected from morpholinyl, piperazinyl, piperidinyl or pyrrolidinyl wherein said Het² is optionally substituted with one or where possible two or more substituents selected from hydroxy, amino or C₁₋₄alkyl-;

In a further embodiment Het² represents a heterocycle selected from morpholinyl or piperidinyl optionally substituted with C₁₋₄alkyl-, preferably methyl;

Het¹⁴ represents morpholinyl;

Het¹⁶ represents a heterocycle selected from morpholinyl or pyrrolidinyl;

Het²⁰ represents pyrrolidinyl or piperidinyl;

Ar⁴ represents phenyl;

Ar⁵ represents phenyl optionally substituted with cyano.


4. A compound according to claim 1 or 2 wherein the R¹ substituent is at position 4', the R² substituent is at position 5', the R³ substituent is at position 3 and the R⁴ substituent at position 7 of the structure of formula (I).

5. A compound according to any one of claims 1 to 4 wherein a¹-a²=a³-a⁴ represents N-CH=CH-CH.

6. A compound according to any one of claims 1 to 4 wherein a¹-a²=a³-a⁴ represents N-CH=N-CH.

7. A compound according to any one of claims 1 to 4 wherein a¹-a²=a³-a⁴ represents CH-CH=N-CH.

8. An intermediate of formula



the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein

a¹-a²=a³-a⁴ represents a divalent radical selected from N-CH=CH-CH or N-CH=N-CH;

Y represents -C₃₋₉alkyl-, -C₁₋₅alkyl-NR¹³-C₁₋₅alkyl-, -C₁₋₆alkyl-NH-CO- or -CO-NH-C₁₋₆alkyl- ;

R¹ represents hydrogen or halo;

-56-

R² represents hydrogen, cyano, halo, hydroxycarbonyl-, C₁₋₄alkyloxycarbonyl-,
Het¹⁶-carbonyl- or Ar⁵;

R⁴ represents hydroxy, C₁₋₄alkyloxy-, Ar⁴-C₁₋₄alkyloxy or R⁴ represents C₁₋₄alkyloxy
substituted with one or where possible two or more substituents selected from
5 C₁₋₄alkyloxy- or Het²-;

R¹¹ represents hydrogen;

R¹³ represents Het¹⁴-C₁₋₄alkyl;

Het² represents a heterocycle selected from morpholinyl, piperazinyl, piperidinyl or
pyrrolidinyl wherein said Het² is optionally substituted with one or where possible
10 two or more substituents selected from hydroxy, amino or C₁₋₄alkyl-;

Het¹⁴ represents morpholinyl;

Het¹⁶ represents a heterocycle selected from morpholinyl or pyrrolidinyl;

Ar⁴ represents phenyl;

Ar⁵ represents phenyl optionally substituted with cyano.

15

9. A kinase inhibitor of formula (I) or formula (XXXI).

10. A compound as claimed in any one of claims 1 to 7 for use as a medicine.

20

11. Use of a compound as claimed in any one of claims 1 to 7 in the manufacture of a
medicament for treating cell proliferative disorders such as atherosclerosis,
restenosis and cancer.

25

12. A pharmaceutical composition comprising a pharmaceutically acceptable carrier
and, as active ingredient, an effective kinase inhibitory amount of a compound as
described in any one of the claims 1 to 7.

13. An intermediate as claimed in claim 8 for use as a medicine.

30

14. Use of an intermediate as claimed in claim 8 in the manufacture of a medicament
for treating cell proliferative disorders such as atherosclerosis, restenosis and
cancer.


35

15. A pharmaceutical composition comprising a pharmaceutically acceptable carrier
and, as active ingredient, an effective kinase inhibitory amount of an intermediate
as claimed in claim 6.


16. A process for preparing a compound as claimed in claims 1 to 7, comprising;

-57-

a) coupling 2-acetoxy-8-chloropyrimido[5,4-d]pyrimidine derivatives (II) with suitable substituted anilines (III), to furnish the intermediates of formula (IV), and deprotecting the intermediates of formula (IV) followed by ring closure under suitable conditions.



b) coupling the known 8-chloro-2(methylthio)-pyrimido[5,4-d]pyrimidine with 2-aminophenol derivatives of formula (XXI), yielding the intermediate compounds of formula (XXII). Next, the pyrimido[3,2-d]pyrimidine of formula (XXII) is aminated using an aminated alcohol (XXIII) under art known conditions, followed by ring closure under Mitsunobu conditions to give the target compounds of formula (I'')



-58-

17. A method of treating a cell proliferative disorder, the method comprising administering to an animal in need of such treatment a therapeutically effective amount of a compound as claimed in any one of claims 1 to 7.
- 5 18. A method of treating a cell proliferative disorder, the method comprising administering to an animal in need of such treatment a therapeutically effective amount of an intermediate as claimed in claim 8.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/053501

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D498/18 C07D471/18 C07D471/04 C07D487/04 A61K31/519
A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 95/19774 A (WARNER-LAMBERT COMPANY) 27 July 1995 (1995-07-27) Scheme 4	1,8,11, 12,14, 15,17,18
A	WO 97/32880 A (DR. KARL THOMAE GMBH) 12 September 1997 (1997-09-12) cited in the application claims	1,8,11, 12,14, 15,17,18

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

19 April 2005

Date of mailing of the international search report

28/04/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Diederer, J

INTERNATIONAL SEARCH REPORT

national application No.
PCT/EP2004/053501

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 17,18 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2004/053501

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9519774	A	27-07-1995	US 5654307 A 05-08-1997
			AU 686334 B2 05-02-1998
			AU 1731495 A 08-08-1995
			AU 686339 B2 05-02-1998
			AU 1833495 A 08-08-1995
			BG 63245 B1 31-07-2001
			BG 100614 A 31-03-1997
			BG 63432 B1 31-01-2002
			BG 100615 A 28-02-1997
			CA 2177372 A1 27-07-1995
			CA 2177392 A1 27-07-1995
			CN 1493291 A 05-05-2004
			CN 1139383 A ,C 01-01-1997
			CN 1139430 A ,C 01-01-1997
			CZ 9601970 A3 17-09-1997
			CZ 9601971 A3 16-07-1997
			EP 0742717 A1 20-11-1996
			EP 0741711 A1 13-11-1996
			FI 962855 A 13-09-1996
			FI 962856 A 25-09-1996
			FI 20040648 A 07-05-2004
			FI 20040649 A 07-05-2004
			HR 950033 A1 31-10-1997
			HR 950034 A1 31-10-1997
			HU 74590 A2 28-01-1997
			HU 74589 A2 28-01-1997
			IL 112249 A 25-11-2001
			JP 9508126 T 19-08-1997
			JP 9508127 T 19-08-1997
			MD 960211 A 30-04-1998
			MD 960217 A 30-04-1998
			NO 963093 A 24-07-1996
			NO 963094 A 24-07-1996
			NZ 281011 A 01-02-2002
			NZ 281404 A 28-05-1999
			PL 315632 A1 25-11-1996
			PL 315633 A1 25-11-1996
			RO 117257 B1 28-12-2001
			RU 2174980 C2 20-10-2001
			SK 89496 A3 08-10-1997
			SK 89596 A3 06-08-1997
			TJ 381 B 16-04-2004
			UA 62028 C2 15-12-2003
			WO 9519970 A1 27-07-1995
			WO 9519774 A1 27-07-1995
			US 6521620 B1 18-02-2003
			US 6265410 B1 24-07-2001
			US 2003186987 A1 02-10-2003
			US 5679683 A 21-10-1997
WO 9732880	A	12-09-1997	DE 19608588 A1 11-09-1997
			AT 252101 T 15-11-2003
			AU 730376 B2 08-03-2001
			AU 2094597 A 22-09-1997
			BG 63163 B1 31-05-2001
			BG 102789 A 30-09-1999
			BR 9707839 A 27-07-1999
			CA 2248720 A1 12-09-1997

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2004/053501

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9732880	A	CN 1212694 A ,C	31-03-1999
		CZ 9802815 A3	17-02-1999
		DE 59710864 D1	20-11-2003
		EE 9800278 A	15-02-1999
		WO 9732880 A1	12-09-1997
		EP 0888351 A1	07-01-1999
		HK 1018450 A1	13-07-2001
		HU 9902049 A2	28-10-1999
		JP 2000506151 T	23-05-2000
		NO 984082 A	04-09-1998
		NZ 331545 A	27-03-2000
		PL 328719 A1	15-02-1999
		RU 2195461 C2	27-12-2002
		SK 120898 A3	11-02-1999
		TR 9801755 T2	21-12-1998
		TW 454008 B	11-09-2001
		US 5821240 A	13-10-1998
		ZA 9701887 A	07-09-1998